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ABSTRACT

EPIGENETIC CONTROL OF INNATE LYMPHOID CELL HOMEOSTASIS AND
DEVELOPMENT
Walter K. Mowel
Jorge Henao-Mejia

Commitment to the innate lymphoid cell (ILC) lineage is determined by Id2, a
transcriptional regulator that antagonizes T and B cell-specific gene expression programs.
Yet how Id2 expression is regulated in each ILC subset remains poorly understood.
Emerging data suggests that epigenetic regulation by long non-coding RNAs (lncRNAs)
plays a critical role in cell type-specific regulation of gene expression in immune cells. In
this thesis, we identified a cis-regulatory element demarcated by a lncRNA that controls
the function and lineage identity of group 1 ILCs, while being dispensable for early ILC
development and homeostasis of ILC2s and ILC3s. The locus encoding this lncRNA,
which we termed Rroid, directly interacted with the promoter of its neighboring gene, Id2,
in group 1 ILCs. Moreover, the Rroid locus, but not the lncRNA itself, controlled the identity
and function of ILC1s by promoting chromatin accessibility and deposition of STAT5 at the
promoter of Id2 in response to interleukin (IL)-15. Furthermore, a second regulatory
element, which we called Id2-DS3, regulated ILC2 levels by promoting their early
development. Thus, this study suggests that non-coding elements responsive to
extracellular cues unique to each ILC subset represent a key regulatory layer for
controlling the identity and function of ILCs.
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CHAPTER 1: Introduction
1.1 Innate lymphoid cells: an overview
The mammalian immune system employs a diverse array of cell types across
nearly every tissue in the body to accomplish an equally diverse array of biological
functions, from protection against invading pathogens to maintaining metabolic
homeostasis, tissue repair, tumor cell surveillance, and many others. Over the past
several years, new groups of innate lymphocytes, termed innate lymphoid cells (ILCs),
have emerged as key regulators of these processes1,2. However, the specific factors
governing the transcriptional regulation of ILC development, homeostasis, and effector
responses are still largely unknown. In particular, specific epigenetic factors such as
enhancers, super-enhancers, and long non-coding RNA (lncRNA) transcripts have key
roles in innate and adaptive immune cells but have not been studied in the context of ILC
biology.
The overall aim of this thesis is to elucidate new transcriptional and epigenetic
regulatory elements critical for the control of ILCs. In Chapter 2, we characterize lncRNA
expression in ILCs and find that they are specifically expressed in ILC lineages. In
particular, we show that the lncRNA Rroid is highly expressed in group 1 ILCs and
regulates their homeostasis but is dispensable for other ILCs. In Chapter 3 we show that
Rroid is required for group 1 ILC maturation by regulating expression of the key ILC gene
Id2. In Chapter 4 we show that DNA regulatory elements in the Rroid locus forms
chromatin loops to promote chromatin accessibility at the Id2 promoter to promote STAT5
deposition and activation of Id2 transcription in response to IL-15. Finally, in Chapter 5
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we show that an Id2 regulatory region is critical for promoting ILC2 homeostasis but is
dispensable for group 1 ILCs and ILC3s.
In Chapter 1, we summarize our current understanding of transcriptional
regulation in ILC development and maturation, as well as the roles of epigenetics on these
processes, with a particular focus on the roles that long non-coding RNAs play in immune
cell development and responses.

1.1.1 Overview of ILC biological function
Although ILCs arise from lymphoid precursors, they do not express the rearranged
antigen receptors typical of B and T lymphocytes, and they do not express the lineagedefining markers of innate myeloid cell populations3. Instead, ILCs have been functionally
categorized based on the basis of the effector cytokines they produce, as well as by
expression of specific transcription factors and gene expression programs. ILCs are
divided into three main lineages analogous to CD4+ helper T cell subsets3. Group 1 ILCs
are comprised of cytotoxic Natural Killer (NK) cells and helper-like ILC1s that express the
transcription factor T-bet and the Th1-associated cytokine interferon (IFN)-g. Group 2 ILCs
are comprised by ILC2s which are marked by the transcription factor GATA3 and express
the Th2-associated cytokines IL-5 and IL-13 upon stimulation. Finally, group 3 ILCs are
comprised of NKp46+ ILC3s, NKp46- ILC3s, and lymphoid tissue inducer (LTi) cells, and
are marked by expression of the transcription factor RORgt and express the Th17 cellassociated cytokines IL-17 and IL-222 (Figure 1A).
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ILCs are distributed throughout the body and, with the exception of NK cells and
some inflammatory settings, ILCs are thought to be tissue resident cells that both provide
for defense against pathogens and support the functions of the tissues in which they
reside1,4-6 (Figure 1A). For example, ILC1s are activated by cytokines such as IL-12, IL15, and IL-18, and are a key innate source of IFN-g in the context of mucosal Toxoplasma
gondii, Clostridium difficile, and Salmonella Typhimurium infections7-9.
ILC2s are activated by a variety of stimuli including to epithelial-derived alarmins
IL-25, IL-33, and TSLP to secrete IL-5 and IL-13 upon stimulation and are thus important
in promoting the clearance of helminth parasites through recruitment of additional immune
cell subsets and induction of mucus production in the lung and gut10. Lung resident ILC2s
also promote tissue repair and lung homeostasis following influenza A infection through
production of the EGFR ligand Amphiregulin, while adipose tissue-resident ILC2s maintain
metabolic homeostasis11-13.
ILC3s primarily reside in the gut where they are activated by the cytokines IL-1b
and IL-23, and are critical innate sources of cytokines such as IL-17, IL-22, and GM-CSF
that are important for defense of Citrobacter rodentium, and the maintenance of oral
tolerance and barrier integrity in the gut14-16. LTi cells, a subset of RORgt ILC3s promote
the development of lymphoid organs through expression of cell surface lymphotoxin-ab
(LTab) an interactions with LTb receptor (LTbR) on stromal cells17. More recent work has
also identified a novel ILC subset, termed ILCregs, that produces IL-10 and TGF-b to
suppress other gut ILC populations and protect against chemically-induced colitis, but their
additional functions and how they are regulated is still unclear18.
3

While ILCs are critical for defense against pathogens and in regulating tissue
homeostasis, dysregulation of ILC homeostasis and responses have also been linked to
pathological states. For example, ILC2s have been linked with promoting energy
expenditure and adipose tissue function but are lost in the context of obesity in mice and
humans1,12,19. Instead, expansion of IFNg+ NK cells and ILC1s in adipose tissue is
associated with obesity and insulin resistance5,20. Furthermore, dysregulation of ILC1s,
ILC2s, and ILC3s have been associated with susceptibility to cancer, inflammatory bowel
disease, asthma, and allergic responses21-32. Therefore, understanding how ILCs are
regulated at the transcriptional and epigenetic levels will be a key step to understanding
how to modulate these pathways for therapeutic use. Below, we summarize recent
progress in elucidating the transcriptional and epigenetic regulation in the development
and homeostasis of these cells.

1.1.2 Development of ILC precursors
ILCs are divided into three different categories called group 1 ILCs, group 2 ILCs,
and group 3 ILCs based on their transcription factor expression and cytokine production
profiles. All of these ILC populations are thought to rise from common precursor cells. The
earliest known precursors of ILCs are termed early ILC progenitors (EILPs)33. EILPs
themselves are marked by expression of TCF-1 (encoded by Tcf7) and arise from
common lymphoid progenitors (CLPs) to further give rise to common helper ILC
progenitors (CHILPs), PLZF+ ILC progenitors (ILCPs), NK cell progenitors (NKPs), and all
mature ILC populations34,35 (Figure 1B). EILPs derive from lymphoid progenitors and
require expression of the transcription factors TCF-1, NFIL3, and TOX for their
4

development, as Tcf7-/-, Nfil3-/-, and Tox-/- mice all lack EILPs, CHILPs, and mature ILCs.
At this stage, EILPs also express the key ILC transcriptional regulator Id2 and the
transcription factor Gata3, both of which are required for ILC development7,11,36-42. Indeed,
mice lacking the Id2 gene have reduced populations of EILPs and have no CHILPs and
mature ILCs34. Thus, these data suggest different temporal requirements for NFIL3, TCF1, and Id2 in the generation of EILPs and CHILPs, where TCF-1 and NFIL3 are required
for the earliest precursors of ILCs, and Id2 promotes the differentiation of committed ILC
precursors35,43.
In addition, a second population of ILC precursors expressing a4b7 integrin (a4b7+
lymphoid precursor; aLP) thought to give rise to all ILC populations have been described
in fetal liver and adult bone marrow43,44. However, single cell analysis of this population
has shown that these cells express high levels of TCF-1, while others show that aLP rarely
express this gene43,45. One explanation for this discrepancy might be adult vs. fetal origin
of the cells being analyzed. Additionally, some aLP cells expressed genes such as Rorc,
a marker of committed ILC3s. Thus, additional studies combining both single cell
transcriptomics, in vitro clonal assays, and in vivo genetic approaches will be required to
clarify the relationship between aLP, EILP, and their mature ILC progeny.
Following the development of CHILPs, the helper ILCs, including ILC1s, ILC2s,
and ILC3s, diverge from the LTi and NK cell lineages (Figure 1B). The evidence for this
comes from the discovery of a bone marrow ILC precursor expressing the transcription
factor PLZF (encoded by Zbtb16; PLZF+ ILCPs) that gave rise to ILC1, ILC2, and ILC3,
but not LTi or NK cells46. Additionally, while CHILPs require Id2, NKPs and immature NK
5

cells develop independently of Id2 in a manner that is dependent on compensation by
expression of a related protein, Id347,48. These PLZF+ ILCPs then go on to give rise to
helper ILCs, although further studies are required to determine whether these cells directly
upregulate mature ILC genes, or whether they give rise to additional lineage-specific
precursors. In the following sections, we summarize the current understanding of the
development and homeostasis of mature ILC lineages.

1.1.3 Group 1 ILCs
Group 1 ILCs are comprised of both circulating NK cells and tissue-resident ILC1s
that can be found throughout the body. The existence of two separate lineages of
“cytotoxic” NK cells and “helper” ILC1, their developmental origins, and transcriptional
regulation have been controversial since the first descriptions of the ILC lineage in the late
2000s, and have only recently begun to be resolved7,49,50. Thus, few studies deal
specifically with the development and transcriptional regulation, development, and
maturation of ILC1s. Currently much more is known regarding the development of NK cells
from NK cell progenitors (NKPs).
Although the specific signals and steps leading to NKPs in the bone marrow are
poorly understood, STAT5-dependent signals from IL-15 are critically important. NKP cells
upregulate CD122 (IL-2Rb, encoded by Il2rb), a component of the IL-15 receptor, and also
upregulate Eomes, a transcription factors that promotes the development, maturation, and
effector functions of NK cells49,51. Indeed, IL-15-dependent signaling through STAT5 is a
key step in NK cell and ILC1 development, as group 1 ILCs in Il15-/- and STAT5-deficient
6

mice fail to develop and mature, and display profound defects in activation and cytokine
production7,52. The development of these cells is also known to require the transcription
factors NFIL3 and TOX51,53 (Figure 1B). Although the exact mechanisms through which
TOX promotes NKPs is not known, NFIL3 likely contributes to this process by inducing
expression of key genes Eomes and Id2 by directly binding their promoters51.
Surprisingly, the transcriptional regulator Id2, critical for the development of
CHILPs, all helper ILCs, and mature NK cells is not required for the generation of NKPs
in the bone marrow47. This discrepancy has been attributed to compensation by Id3, an
Id-family member closely related to Id2, in early NK cell development47,48. Nonetheless,
Id2 is required to promote the later stages of NK cell maturation. In the mouse, NK cells
are known to undergo a maturation cycle consisting of three phases marked on the basis
of CD27 and CD11b expression: CD27+ CD11b- ® CD27+ CD11b+ ® CD27- CD11b+54.
Two recent studies showed that Id2 regulates the transition to the CD27+ CD11b+
phenotype by promoting the proliferation and survival of these cells48,55. Expression of
both T-bet and the transcription factor Zeb2 are also required for the final maturation
stages of NK cells, as both Tbx21-/- and Zeb2-/- mice lack CD27- CD11b+ mature NK
cells7,56-58.
While the maturation of NK cells has been studied, the pathways controlling
maturation ILC1s are largely unknown. This is partially due to the fact that until recently,
precursors giving rise to ILC1s, but not NK cells, were not known. Early studies
characterizing Eomes- TRAIL+ NK cells in the liver postulated that these cells were a
population of immature NK cells that subsequently gained Eomes expression56. However,
subsequent studies have identified these cells as ILC1s that develop from CHILPs and
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PLZF+ ILCPs, do not upregulate Eomes, but require T-bet for their homeostasis7,49,50.
Thus, in light of these findings, some cell populations formerly thought to be tissue resident
NK cells in additional tissues such as the thymus, salivary glands, and adipose tissue may
actually be derived from ILCPs, and thus may be categorized ILC1s. Future studies reexamining the development of these different tissue resident NK/ILC1 populations using
genetic and lineage-tracing tools will be required to disentangle the contributions of each
group 1 ILC lineage to these compartments.

1.1.4 Group 2 ILCs
Group 2 ILCs consist solely of ILC2s, which are distributed in tissues throughout
the body where they perform effector functions and maintain tissue homeostasis. Although
GATA3 is expressed in bone marrow ILC precursors and required for their generation,
high levels of GATA3 mark ILC2 precursors (ILC2P) and mature ILC2s, and supports their
effector function36. ILC2 precursors arise from CHILPs and PLZF+ ILCP in the bone
marrow, a process that is additionally promoted by the transcription factors Bcl11b, Gfi1,
and RORa36,59-63 (Figure 1B). Califano, et al.60 showed that Bcl11b is upstream of GATA3
as it is recruited the promoter of Gfi1 to activate its expression, and ectopic expression of
Gfi1 in Bcl11b-/- ILC2s was sufficient to rescue GATA3 expression. Relatively less is known
about the maturation of ILC2s. Acquisition of the surface receptor ICOS by ILC2s, and its
interaction with its ligand ICOS-L, was shown to promote the maturation and survival of
ILC2s by promoting STAT5 signaling and thus survival and effector functions of these
cells64.
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Like group 1 ILCs, ILC2s are dispersed throughout the body, where they are tissue
resident and play important roles in regulating tissue homeostasis2. Interestingly, ILC2s
residing in different tissues have distinct gene expression patterns are induced by tissuespecific signals65. This implies that downstream transcriptional regulators may control
ILC2s in a tissue-specific manner. For example, a recent study reported that the ETS1
transcription factor promotes ILC2 populations in the mesenteric lymph nodes, but is not
required at steady state in lung ILC2s66. Thus, tissue-specific transcriptional control of
ILC2 homeostasis and responses is likely to be a key emerging area of ILC2 biology.

1.1.5 Group 3 ILCs
Group 3 ILCs are composed of heterogeneous populations of RORgt+ innate
lymphocytes, and are generally divided into three different populations: NKp46+ ILC3s,
NKp46- ILC3s and LTi cells marked by CCR6 or CD440,67,68, each of which is primarily
restricted to the intestine and its associated lymphoid tissues. The transcription factor
RORgt not only marks ILC3s, but is also required for their development, and imparts key
effector functions such as the ability to produce IL-22 and IL-17. Environmental signals
play a key role in the maintenance of ILC3s, as multiple transcription factors that respond
to environmental signals have been discovered to regulate RORgt expression, and thus
ILC3 development and function. For example, maternal retinoids regulate the activity of
ILC3-intrinsic RARa expression in utero to regulate the development of secondary
lymphoid organs by promoting the development of LTi cells69. Mice deficient in RARa had
reduced, lymph nodes and Peyer’s patches, and were more susceptible to infection.
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Likewise, mice fed a vitamin A-deficient diet, or in which RARa was inducibly deleted in
ILC3s exhibit pronounced ILC3 defects and profound susceptibility to bacterial
infections70. Another key transcriptional regulator controlling the homeostasis of ILC3s is
the aryl hydrocarbon receptor (AHR)26,71,72. Signals derived from food and the microbiota
activate AHR to promote the rapid proliferation, maintenance, and IL-22 cytokine
production of postnatal ILC3s71,72. As such, AHR deficiency does not alter the number of
CCR6+ LTi cells, as these cells primarily develop in utero.
Surprisingly, another key regulator of a subset of ILC3s is T-bet, which is required
for the development of ILC1s, but is co-expressed along with RORgt in some ILC3s9,73,74.
At steady state, IL-23 signaling to ILC3s is required to upregulate T-bet in a subset of
ILC3s, and this drives the acquisition of NKp46+ ILC3s. It also imparts in them the ability
to produce IFN-g in response to stimulation by IL-12 in response to Salmonella infection9.
T-bet-dependent ILC3s were also shown to be required for appropriate IL-22 production
and responses to Citrobacter infection74. Interestingly, exposure of NKp46+ ILC3s to IL12, IL-15, and IL-18 can induce the downregulation and loss of RORgt, resulting in an
ILC1-like phenotype75. These “ex-ILC3s” retain the ability to produce IFN-g in response to
IL-12 and in colitis model in vivo. However, the pathways leading to the development of
ex-ILC3s and their role in immune responses in vivo are currently poorly understood.

1.1.6 Epigenetic regulation of ILCs
As discussed above, ILCs at all development stages and of all lineages express a
wide variety of transcription factors that are critical for their development and function.
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These transcription factors bind to gene promoters, enhancers, silencers, and other
regulatory elements to control gene expression. However, the large size of mammalian
genomes necessitates that chromosomal DNA is tightly wrapped around histones and
condensed into chromatin, obscuring the binding sites utilized by those transcription
factors. Thus, an additional layer of regulation of ILC development and function is at the
epigenetic level, in controlling the landscape of chromatin that is “open” and accessible to
transcription factors, or through modulating the activity of those transcription factors at
specific loci. Accessible chromatin can now be assessed by high-throughput sequencing
methodologies such as ATAC-seq76, while other regulatory elements such as enhancers
and promoters can be identified by chemical modifications made to histone tails77,78. For
example, the addition of an acetyl group to lysine 27 of histone H3 (H3K27ac) marks
enhancers and active genes, while mono- and di-methylation of lysine 4 of histone H3
(H3K4me1 and H3K4me2) has been shown to mark enhancers specifically, and
trimethylation (H3K4me3) marks promoters of actively transcribed genes78.
Recent studies have shown that each ILC lineage bears a unique epigenetic
signature that changes depending on activation state and presence of microbial
signals79,80. Early work showed that the Ifng promoter is held in an accessible
conformation, and that Ifng mRNA is constitutively expressed in NK cells81-83. ILC2s are
also regulated by G9a, a methyltransferase that dimethylates lysine 9 of histone H3
(H3K9me2), a mark of silenced genes84. G9a is required for silencing of Rorc and Il17f in
ILC2s, and as such G9a-/- deficient ILC2s display ILC3-like properties84. However, the role
of epigenetic regulation in ILC homeostasis and effector responses is only just beginning
to be studied. Moreover, understanding the mechanisms of epigenetic regulation in ILCs
11

may have important therapeutic potential, as activation of enhancers and superenhancers marked by H3K4me2 modifications in activated human ILC2s are located
proximal to loci known to harbor disease-associated SNPs in asthma susceptibility in
humans32.
In addition to the control of gene expression by transcription factors and accessible
chromatin, non-protein coding transcription has recently been described as an additional
key regulatory layer controlling chromatin accessibility, transcription of key protein-coding
genes, mRNA transcript stability, and transcription factor activity in ILCs. For example,
microRNAs (miRNAs) such as miR155 and the miR17~92 cluster have been shown to
regulate ILC2 numbers and cytokine responses85,86. However, transcriptional regulation
by long non-coding RNAs (lncRNAs) has recently emerged as a key mechanisms of
epigenetic gene regulation in the immune system but has scarcely been studied in ILCs.
Indeed, during the course of the studies described in this thesis, only one other study has
addressed the role of lncRNAs, lncKdm2b, in the maintenance of ILC3s87. Taken together
with previous findings reporting key roles for lncRNAs in innate and adaptive immune cells,
this suggests that lncRNAs likely play important roles in the regulation of ILC homeostasis.
Thus, in the following sections, we provide broad overview of how, through diverse
mechanisms of action, lncRNAs tightly control the function and homeostasis of immune
cells.
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1.2 Overview of long non-coding RNAs in the immune system
1.2.1 lncRNA introduction
A longstanding observation in biology is that while the number of protein coding
genes has remained relatively stable across multicellular organisms, the genomic content
of non-coding DNA increases with the developmental complexity of organisms88. This
seemingly paradoxical finding, termed the G-value paradox, suggests that the degree of
regulatory control exerted by non-coding regions over protein-coding genes determines
phenotypic complexity, which has increased throughout evolution88. In support of this
inference, a number of high-throughput sequencing studies have recently shown that a
great proportion of the mammalian non-coding genome comprises an immense network
of cis-regulatory elements such as promoters, enhancers, and super-enhancers77,89-91.
Strikingly, these studies also showed that nearly 70% of the human non-coding genome
shows evidence of transcriptional activity. The function of the majority of these non-coding
transcripts is unknown; nevertheless, several classes of non-coding RNAs have been
found to contribute to the transcriptional and epigenetic regulation of gene expression
programs. Among these functional non-coding RNAs, lncRNAs are the most abundant
and have been extensively studied in recent years.
A diverse array of cells from the innate and adaptive immune system orchestrate
protective immune responses that clear infections while preventing the deleterious
consequences of prolonged inflammation. The highly-specialized functions of each of
these immune cell types are determined by their unique transcriptional programs. While
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much is known about how transcription factors and different extracellular cues regulate
the development and functional specialization of innate and adaptive immune cells, our
knowledge regarding the roles of lncRNAs in the immune system is in its infancy. A
growing body of evidence indicates that lncRNAs are expressed in a more cell typespecific manner than protein-coding genes and are rapidly induced by unique tissuederived and environmental signals92,93. As such, these molecules have emerged as highly
cell type-specific regulators of gene expression programs in the immune system. Thus, in
the following sections we provide an overview of the roles of lncRNAs in the immune
system, and the mechanisms through which lncRNAs accomplish those roles.

1.2.2 Mechanisms of action of lncRNAs Functional lncRNAs
LncRNA molecules themselves can directly interact with proteins, DNA, and other
RNAs to exert their functions (Figure 2). Nevertheless, not all lncRNA loci that are
biologically active depend on the function of the RNA molecule itself. Therefore, to simplify
our understanding of lncRNA mechanisms we separate them into three different
categories: (i) lncRNA loci in which the RNA molecule itself is functional, (ii) lncRNA loci
in which the act of transcription, but not the lncRNA molecule, has a functional role, and
(iii) lncRNAs that represent proxy signals for active cis-regulatory elements. In this section,
we aim to exemplify each functional grouping with lncRNA loci described in the immune
system, where they exist. In the following sections we describe in detail the biological
process they regulate in the context of innate immune cell development and responses.
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The first lncRNAs were characterized by demonstrating direct biological activity of
the lncRNA molecule itself94-96. This remains the gold standard for characterizing lncRNA
loci. Functional lncRNAs can localize to the nucleus or cytosol to specifically interact with
proteins, DNA, or other RNAs to perform their molecular functions. Conceptually, it is
helpful to group these functional lncRNAs within two classes: those that serve as inhibitors
and those that serve as facilitators of binding partner interactions.

Class I of functional lncRNAs: Inhibitors – keeping things apart
Many protein-protein interactions conform to a classic molecular decoy model,
wherein the decoy molecule binds to and inhibits one partner in an interaction; a classic
example of this is the non-signaling interleukin 1 receptor type 2 (IL1R2), which binds the
cytokine IL-1b and prevents it from signaling through its normal receptor97. Here we can
expand this concept to include lncRNA-mediated processes in which factors are inhibited
from interacting with one another (Figure 2A). This class includes lncRNAs that act as
sinks for microRNAs, such as the lncRNA Phosphatase And Tensin Homolog Pseudogene
1 (PTENP1), whose 3’ UTR binds the same set of miRNA sequences that normally target
the tumor-suppressor gene PTEN98. In addition, this also includes lncRNAs that
specifically inhibit classical protein-protein interactions such as the lncRNA lnc-DC99. LncDC regulates the differentiation and activation profile of dendritic cells (DCs) in humans
by binding STAT3 in the cytosol and preventing its dephosphorylation and inactivation by
the tyrosine phosphatase SHP199. The inhibitory class includes lncRNAs that block
protein-DNA interactions, such as pseudogene-derived lncRNA Lethe100. Lethe physically
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associates with NF-kB p65 (RelA) subunit and directly or indirectly blocks its recruitment
to the promoters of certain immune genes such as IL6 and IL8100. Notably, these lncRNAs
can directly act post-transcriptionally, as their function is not dependent on the process of
translation. Thus, lncRNAs can exert rapid and potent biological outcomes in the immune
system by blocking key DNA, RNA, or protein interactions.

Class II of functional lncRNAs: Facilitators – bringing things together
LncRNAs have been described to form complexes with protein, RNA,
and/or DNA, and thus facilitate the interaction of specific binding partners. This class of
RNA-dependent mechanism includes lncRNAs that serve as “scaffolds” or “guides”
(Figure 2B). “Scaffold” lncRNAs can function as molecular platforms upon which other
DNA, RNA, and protein molecules can assemble. For example, in ILC3s the lncRNA
lncKdm2b acts as a scaffold for the recruitment of Sat1b and members of the NURF
chromatin remodeling complex to the Zfp292 promoter87. Similarly, the lncRNA myeloid
RNA regulator of Bim induced death (Morrbid) silences its neighboring pro-apoptotic gene
Bcl2l11 (Bim) in an allele specific manner by promoting the enrichment of polycomb
repressive complex 2 (PRC2) within the Bcl2l11 promoter101. Of note, the general model
of direct lncRNA-directed recruitment of proteins is complicated by the lack of known
protein-binding motifs within lncRNAs. Thus, future studies on lncRNA motifs, such as
presence of short k-mer motifs, and structure are needed to better understand how
lncRNAs interact with specific proteins and how lncRNAs localize to specific sites102,103.
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1.2.3 Mechanisms of action of lncRNAs: a functional role for transcription across
lncRNA loci
As previously discussed, lncRNAs demonstrate cell type-specific expression and
many are responsive to specific extracellular cues. Because the transcription of lncRNAs
is strictly regulated, and because many lncRNAs impact the expression of neighboring
genes, it has been suggested that the process of transcription and/or splicing of lncRNAs
may impact the expression of proximal genes through the recruitment of specific protein
factors104-106 (Figure 2C). This was recently dissected in further detail through the study
of the protein coding gene Sfmbt2 and its neighboring lncRNA Blustr107. The authors found
that Sfmbt2 is upregulated by the splicing and transcription of Blustr, in a mechanism
independent of the sequence of Blustr but likely involved the recruitment of polymerases
and chromatin modifying factors107. By inserting a synthetic polyadenylation sequence at
different locations within this locus in vitro, the effects of Blustr on Sfmbt2 transcriptional
activation were determined to be dependent on the length of transcription across the Blustr
locus107. In parallel, Anderson et al.108 demonstrated in vivo that the heart development
regulator Hand2 is controlled in cis by the lncRNA Upperhand (Uph), but that this control
was independent of the sequence of Uph108. Transcription of Uph was required to maintain
the chromatin state of a cardiac super-enhancer-like element within the Uph locus108.
Thus, transcription of lncRNA loci is likely to play a key role in regulating gene expression
in cis in a variety of contexts. However, the role of transcription across lncRNA loci in
immune cells is yet to be determined.
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1.2.4 lncRNAs are proxy signals for key cis-regulatory elements
The promoters of many lncRNA loci are conserved across species and have
enhancer chromatin signatures, suggesting that certain lncRNA promoters may function
as cis-acting enhancer elements that result in bystander noncoding transcripts107,109.
Given that lncRNA loci frequently contain or are in close proximity to important regulatory
DNA elements, the production of lncRNAs from these loci can delineate critical cisregulatory DNA elements within these loci (Figure 2D). For example, mapping of RNA
polymerase II using Chromatin Interaction Analysis with Paired-End-Tag sequencing
(ChIA-PET) revealed strong genome-wide promoter-centered intergenic interactions,
suggesting that promoters of coding and non-coding genes may have dual functions as
enhancers110.
Therefore, certain lncRNA transcripts may arise as non-functional by-products, yet
they may serve as proxy signals of the activity of important regulatory elements111. For
example, deletion of the lncRNA down-stream of Cdkn1b (Lockd) locus was found to
impact the transcription of its neighboring gene Cdkn1b; however, pre-mature
polyadenylation of Lockd had no impact on Cdkn1b transcription112. The Lockd promoter
was found to have many enhancer-like features suggesting that this lncRNA locus may
indeed function through DNA elements within its promoter and that the RNA transcript
produced from this locus marks an important regulatory element112. Additionally, the loci
of some previously described lncRNAs have also been found to contain functional
regulatory elements independent their associated lncRNA113,114. Thus, the transcription of
many lncRNAs likely mark key regulatory elements in cells.
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1.2.5 lncRNAs in the innate immune system
In biological immune responses, the cells of the innate immune system –
macrophages, dendritic cells, neutrophils, basophils, eosinophils, and ILCs - must
undergo rapid changes in their gene expression programs to immediately respond to
infection, tissue damage, or other changes in environmental conditions. As discussed
above, one of the key advantages of lncRNA-mediated gene regulation is that existing
pools of transcription factors can be utilized to promote expression of target lncRNAs,
which can then rapidly affect expression of both individual genes or sets of genes within
minutes without requiring new protein synthesis. As such, it is not surprising that many of
the initial discoveries of lncRNAs in the immune system were focused on the regulation of
inflammation in innate immune cells.

lncRNAs regulate inflammatory gene expression in innate immune cells
One of the first lncRNAs described in the immune system, lincRNA-Cox2, was
discovered in bone marrow-derived dendritic cells stimulated with lipopolysaccharide
(LPS), an agonist of TLR4115. Strikingly, lincRNA-Cox2 is rapidly induced within 30 minutes
in RAW264.6 macrophages in response to inflammatory cues116. Carpenter et al.117
showed that this lncRNA regulates a large set of inflammatory response genes, as
knockdown of lincRNA-Cox2 resulted in increased expression of a gene set including Ccl5
and Cx3cl1 (Figure 3A). lincRNA-Cox2 interacts with hnRNP-A/B and hnRNP-A2/B1 in
vitro, and knockdown of both hnRNP-A/B and hnRNP-A2/B1 results in de-repression of
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Ccl5117. In contrast, other work has shown that lincRNA-Cox2 in immortalized macrophage
cell lines interacts with the SWI/SNF chromatin remodeling complex to promote its
recruitment to the Ccl5 promoter and activate transcription116. lincRNA-Cox2 has also
been shown to interact with and recruit the Mi2/NuRD repressive complex to the Il12b
promoter in response to TNF stimulation in intestinal epithelial cell lines to silence Il12b
expression118.
This type of mechanism, wherein lncRNAs act as guides or scaffolds to rapidly
regulate the recruitment chromatin modifying complexes to their target genes, is likely
widespread. Indeed, a recent study identified lnc13, which is downregulated in response
to LPS, as a repressor of genes involved in inflammatory pathways such as Myd88, Stat1,
Stat3, and Il1ra119. This effect is mediated through the regulation of HDAC1 and hnRNPD
recruitment to their target genes in an RNA-dependent mechanism119. Additionally,
lincRNA-EPS suppresses genes such as Cxcl10 and Ccl5 by interacting with hnRNPL and
regulating nucleosomal positioning at these target loci120 (Figure 3B). In vivo, mice
deficient for lincRNA-EPS exhibit significant increases in circulating proinflammatory
cytokines and are extremely susceptible to LPS challenge120.
Constitutively expressed transcription factors in innate immune cells rapidly
transduce signals following TLR ligation, promoting inflammatory gene expression.
lncRNAs regulate this process not only by directing the recruitment of chromatin modifying
complexes to target genes but can also directly control the ability of transcription factors
to form complexes with other proteins or bind their target loci. As described above, one
example of this activity is lnc-DC, which is highly expressed in human DCs and directly
promotes STAT3 activity by preventing its dephosphorylation99. Functionally, this results
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in reduced expression of the costimulatory molecules CD80 and CD86, as well as MHCII99. Thus, lnc-DC and upstream signals regulating its expression may play an important
role in CD4+ T cell priming during in vivo immune responses. Similarly, the lncRNA Lethe
interacts with the p65 subunit of NF-kB to inhibit its binding to the TNF promoter,
negatively regulating TNF production in mouse macrophages, while the lncRNA PACER
blocks the inhibitory NF-kB p50 subunit from binding the COX2 promoter, resulting in
increased COX2 expression in human macrophages in vitro100,121. Altogether, these
studies show that lncRNAs utilize a variety of mechanisms to rapidly regulate inflammatory
gene expression programs in innate immune cells in response to microbial-derived cues,
representing a new and potent regulatory layer in inflammatory responses.

lncRNAs in the development and homeostasis of innate immune cells
While several lncRNAs regulating inflammatory processes have been described in
the literature, very few are yet known to regulate the development or homeostasis of innate
cells. HOTAIRM1 is one such example that is highly expressed in human granulocytes
and induced by retinoic acid signaling and PU.1 during myeloid differentiation122,123.
Knockdown of HOTAIRM1 results in reduced expression of CD11b and CD18 as well as
impaired granulocyte differentiation in cell lines122. However, the role of HOTAIRM1 in the
differentiation of human granulocytes in vivo still unknown.
Recently, we showed that the lncRNA Morrbid controls the homeostasis of
eosinophils, neutrophils, and Ly6Chi monocytes in vivo by regulating the pro-apoptotic
molecule Bcl2l11, also known as Bim101. Morrbid is induced in these short-lived myeloid
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cells in response to pro-survival cytokines and represses Bcl2l11 transcription in an allelespecific manner by promoting the enrichment of the repressive PRC2 complex within the
Bcl2l11 promoter (Figure 3C). In the absence of Morrbid, Bcl2l11 is de-repressed in these
cells, resulting in their apoptosis. This example illustrates a novel and critical pathway
used to precisely regulate the lifespan of these highly inflammatory cell populations.
Indeed, expression of MORRBID is highly upregulated in eosinophils collected from
patients with hypereosinphilic syndrome (HES), a group of disorders characterized by an
altered eosinophil lifespan. Taken together, these data suggest that dysregulation of the
Morrbid-Bcl2l11 axis may be an important element in HES and other disorders of
dysregulated myeloid lifespan such as autoinflammation and cancer.
In ILC3s, lncKdm2b was recently shown to promote ILC3 maintenance and effector
responses in the gut by promoting expression of the transcription factor Zfp29287. Although
the mechanisms through which Zfp292 regulates ILC3s is unclear, the authors showed
that lncKdm2b interacted with the chromatin organizer Satb1 and chromatin remodeling
NURF complex to promote accessible chromatin at the Zfp292 promoter. Thus, lncRNAs
may be key regulators of ILC homeostasis.
Finally, the lncRNA biogenesis and proxy signal-based mechanisms of action are
an emerging field, and as such have not yet been studied in detail in the context of the
immune system. Interestingly, a recent study identified linc1405, a lncRNA expressed
upstream of the Eomes gene in mouse embryonic stem cells107. Deletion of this locus or
its promoter reduced Eomes expression in these cells. However, Eomes-dependent
immune cells, such as natural killer (NK) cells were not examined. Thus, additional studies
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will be required to delineate the potential roles of linc1405 and other lncRNA loci in
immunity.

1.2.6 lncRNAs in human inflammatory disorders
A longstanding observation in human GWAS studies is that more than 90% of
disease-related SNPs are associated with noncoding elements of the genome, and it is
tempting to speculate that mutations in lncRNAs may explain some of these
phenotypes124. Thus far, much of the lncRNA-related research that has been done in the
immune system has focused on delineating the function of lncRNAs in mouse and human
primary cells and cell lines. However, examples have begun to emerge that demonstrate
the importance of lncRNAs in human inflammatory disorders. As we discuss above, the
lncRNA MORRBID is highly upregulated in eosinophils collected from patients with HES,
suggesting the MORRBID-BCL2L11 axis may contribute to this disease101.
In another recent study by Huang, et al.125, the authors show that high levels of the
lncRNA NKILA expressed in tumor-associated CD8+ T cells inhibits NF-kB, sensitizing
them to activation-induced cell death, suggesting that therapeutic modulation of this
pathway could improve clinical outcomes in cancer. A third study found that lnc13, a highly
expressed lncRNA in the healthy human gut, suppresses expression of a subset of
inflammatory disease-related genes and is significantly downregulated in patients with
celiac disease, suggesting that dysregulated lnc13 expression may contribute to
inflammation in this disease119. Indeed, celiac disease-associated SNPs were found in
association with lnc13. Together, the in vivo and in vitro data regarding lncRNAs in the
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immune system suggest that these molecules play key roles in mediating both protection
and susceptibility to inflammatory diseases. In the future, it is critical that robust in vivo
models are developed and utilized to test the physiological consequences of lncRNAs in
inflammatory disorders such as inflammatory bowel disease, diabetes, allergies, asthma,
and cancer, among many others.
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1.3 Figures

Figure 1: Overview of ILC functions and development
(A) Functions of ILC subsets. Group 1 ILCs include NK cells and ILC1s; they are
stimulated to produce type-1 cytokines. Group 2 ILCs produce type 2 cytokines upon
stimulation, while Group 3 ILCs produce type 17 cytokines. (B) EILP are derived from
CLPs in the bone marrow and give rise to all ILC lineages. Downstream, EILPs give rise
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to both helper ILC precursors (CHILP) and NK cell precursors (NKP). CHILPs have the
potential to give rise to all helper ILC populations, including LTi cells. A more restricted
precursor, PLZF+ ILCP, gives rise to only ILC1, ILC2, and ILC3.
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Figure 2: lncRNA mechanisms of action
(A) lncRNA mechanisms that depend on the RNA molecule itself include lncRNA-RNA,
lncRNA-protein, and lncRNA-DNA-based mechanisms. For example, PTENP1
encodes miRNA target sequences shared by PTEN and acts as a “sponge” for
miRNAs targeting PTEN (left). lnc-DC interacts directly with the protein STAT3 and
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blocks its dephosphorylation by the phosphatase SHP-1 (middle). lncRNA Lethe
hinders the recruitment of NF-kB p65 subunit to its target DNA sequences (right).
(B) lncRNAs can activate gene expression by acting as scaffolds for interactions between
other proteins, such as lncKdm2b (left), or as guides to direct the recruitment of
chromatin modifying complexes to neighboring genes, such as Morrbid (right).
(C) The act of lncRNA transcription can intrinsically account for the activity of some
lncRNA loci. Transcription across the lncRNA Blustr directly promotes transcription of
its neighboring gene Sfmbt2.
(D) Some lncRNAs may not regulate transcription of their target genes, but instead act as
a proxy signals for important DNA regulatory elements embedded within the lncRNA
locus.
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Figure 3: lncRNAs in the innate immune system
(A)

LincRNA-Cox2 is induced by TLR ligands and associates with hnRNPA/B and

hnRNPA2/B1 to suppress transcription of target genes, such as Ccl5, and promotes the
expression of genes such as Il6 through a yet unknown mechanism.
(B)

Resting macrophages express high levels lincRNA-EPS, which interacts with

hnRNPL to suppress target genes. Upon stimulation, expression of lincRNA-EPS is
reduced, and repression of these targets is released.
(C)

In short-lived myeloid cells, pro-survival cytokines induce expression of Morrbid,

which acts as a guide to target the repressive PRC2 complex to the Bcl2l11 locus (which
encodes the pro-apoptotic molecule Bim), to promote the survival of these cells.
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CHAPTER 2: The Rroid locus regulates the homeostasis and function of group 1
ILCs

2.1 Abstract
Innate lymphoid cells (ILCs) are located throughout the body and are key players in a
multitude of processes, including defense against pathogens and the maintenance of
tissue homeostasis. However, the specific epigenetic factors governing the transcriptional
regulation of ILC development, homeostasis, and effector responses are still largely
unknown. In particular, whether long non-coding RNAs regulate ILC homeostasis has not
been explored. Here we examine high throughput sequencing datasets to identify
lncRNAs specifically expressed in ILC populations. One of these lncRNAs, Rroid, was
specifically expressed in group 1 ILCs, but not ILC2s or ILC3s. We found that Rroid
specifically regulated group 1 ILCs, as Rroid-/- mice exhibited peripheral NK cell and ILC1
populations that were reduced both in number and functionally, while ILC2s and ILC3s
were not affected. Thus, these data indicate that lncRNAs expressed in ILCs can mark
key regulatory loci in specific ILC lineages, and that Rroid itself specifically marks a critical
regulatory element in group 1 ILCs.
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2.2 Introduction
Innate lymphoid cells are comprised of diverse populations of NK cells, ILC1s,
ILC2s, and ILC3s. Although they are derived from common precursors, these closely
related cells exhibit distinct gene expression profiles126. The contribution of the epigenetic
landscape to gene expression, and therefore cellular identity and effector function, is also
now abundantly clear. The size of mammalian genomes necessitates that the majority
DNA compacted into chromatin, making the “opening” of promoters and cis-regulatory
elements such as enhancers a key regulatory step in making them accessible to
transcription factors and RNA polymerase machinery77,127. Indeed, as ILCs have distinct
transcriptional profiles, they also have distinct epigenetic profiles that depend on and are
regulated by both lineage-dependent and environmental factors such as cytokine and
microbial signals65,77,79,80,84. However, very little is currently known about how specific cisregulatory elements regulate the development, homeostasis, and function of ILCs.
Open, accessible chromatin, certain histone modifications, and even transcription
factor binding can indicate putative cis-regulatory elements. However, a high degree
enhancer redundancy in some cases means that abrogation of any single regulatory
element may not reveal a functional role128,129. Recent evidence has shown that lncRNAs
can play critical roles in directly regulating protein function and gene expression in immune
cells101,130. Transcription of lncRNAs can mark critical cis-regulatory elements, including
enhancers and super-enhancers in a highly cell type-specific manner89,107,131. In addition,
some lncRNAs themselves or the act of transcription along lncRNA loci are known to have
key regulatory functions101,107,117. Together, this has led to the hypothesis that lncRNA
transcription may mark key cis-regulatory elements in specific immune cell subsets130.
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Hence, in this chapter, we describe the discovery, targeting, and functional
characterization of the Rroid locus in group 1 ILCs. We show that the Rroid lncRNA was
highly and specifically expressed in group 1 ILCs, comprised of NK cells and ILC1s, in the
spleen, lung, liver, and intestinal epithelium. Moreover, through genetic deletion, we show
that the Rroid locus controlled the homeostasis and function of group 1 ILCs, but not of
ILC2s or ILC3s. Together, our data show that a lncRNA marks a key locus involved in
regulating group 1 ILCs.
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2.3 Results
2.3.1 The long non-coding RNA Rroid is expressed in group 1 ILCs
Transcription of lncRNAs is known to occur in a highly cell type-specific manner,
and lncRNAs are known to play key roles in regulating gene expression in multiple cells
types, including immune cells89,101,107,117,132,133. Because of this, we hypothesized that
specific expression of lncRNAs in ILC subsets might demarcate unique cis-regulatory
elements critical for the development, function, or homeostasis of individual ILC subsets,
and that these lncRNAs might themselves play key roles in the epigenetic regulation of
ILC gene expression programs. To address this hypothesis, we analyzed multiple
published ATAC-seq and RNA-seq datasets generated from mouse ILC1s, ILC2s and
ILC3s to identify lncRNAs with three main criteria: 1) lncRNAs that were highly expressed;
2) lncRNAs with selective expression in single ILC subsets; and 3) lncRNAs located in the
vicinity of key genes implicated in ILC development or function79,80,134.
Using this approach, we identified a nuclear transcript (Ak083360) that is highly
and specifically expressed in ILC1s, but not ILC2s or CD4+ ILC3s (Figure 4A-D), and that
exhibits all the features of a lncRNA: Ak083360 is 2033nt long, not predicted to encode a
protein, has a multi-exon structure, and is spliced and polyadenylated. This lncRNA is
located ~220kb upstream of Id2, a transcriptional repressor that is a hallmark of all ILC
subsets and is essential for their lineage commitment and the maintenance of mature ILC
identity135 (Figure 4E). Thus, we named this lncRNA Rroid (RNA-demarcated Regulatory
region of Id2).
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Group 1 ILCs are composed of both “helper” ILC1s and cytotoxic ILC1s (NK cells)2.
To establish whether Rroid was also expressed in NK cells, and thus restricted to group 1
ILCs, we determined its expression in multiple lymphoid and myeloid populations and
whole tissues. Indeed, we found that Rroid transcription was preferentially restricted to
both cell types that compose group 1 ILCs (NK and ILC1) and to tissues that are highly
populated by these cell types (Figure 4C-D). Altogether, these data indicated that the
Rroid RNA or cis-regulatory elements within its locus might have key regulatory functions
in group 1 ILCs.

2.3.2 The Rroid locus controls the homeostasis of NK cells and ILC1s, but not ILC2s
or ILC3s
To establish the in vivo physiological relevance of the Rroid locus in the immune
system, we used the CRISPR/Cas9 system to generate mice lacking the region encoding
Rroid (Figure 4E). In concordance with the pattern of expression of this lncRNA, mice
deficient for the Rroid locus (Rroid-/-) exhibited a dramatic reduction in the frequency and
numbers of group 1 ILCs (CD3,CD5- NK1.1+ NKp46+) in the spleen, liver, and lung (Figure
5A-B). In the spleen, the CD3,CD5- NK1.1+ NKp46+ compartment is primarily comprised
of NK cells. In tissues, this phenotype includes both NK cells and ILC1s, and can be
distinguished by differential expression of the surface markers CD49a and CD49b or
expression of the transcription factors Eomes and T-bet7. Rroid-/- mice showed a
significant reduction in liver CD49a+ ILC1s as well as in T-bet+ ILC1s in the lung and
intraepithelial lymphocyte (IEL) compartment in the gut (Figure 5C-E). ILC1 populations
have also been described in the small intestine lamina propria (SI-LPL) and salivary
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glands (SG)7,136. However, we found equivalent numbers of SI-LPL and SG ILC1s (Figure
5E), indicating that the Rroid locus is not required for the homeostasis of these unique
ILC1 populations. Furthermore, we analyzed other lymphoid and myeloid populations in
the spleen, including CD4+ T cells, CD8+ T cells, B cells, macrophages, and dendritic cells,
and did not find any significant differences in the numbers of these cells (Figure 6A-B).
Moreover, intestinal ILC2s and ILC3s, as well as lung ILC2s examined at homeostasis
were not affected in the absence of Rroid (Figure 6C-E). Taken together, these results
indicate that the Rroid locus is specifically required for the homeostasis of both ILC1s and
NK cells in most tissues but is dispensable for ILC2s and ILC3s.

2.3.3 The Rroid locus promotes NK cell responses, but is not required for ILC2 and
ILC3 responses in vitro
We next sought to determine whether the function of group 1 ILCs was altered in
response to inflammatory stimuli. In physiological settings, IL-12 synergizes with IL-15
and/or IL-18 to activate a robust IFN-g response in NK cells and ILC1s (Figure 7A-B). NK
cells can also be activated to degranulate cytotoxic cationic proteins following engagement
of activating receptors such as NK1.1 (Figure 7C-D). However, splenic and liver NK cells
from Rroid-/- mice exhibited a reduced capacity to produce IFN-g in response to cytokine
stimuli (Figure 7A-B). Likewise, Rroid-/- splenic NK cells exhibited reduced expression of
Perforin (encoded by Prf1) and Granzyme B (GzmB) at steady state and failed to
degranulate efficiently upon crosslinking of NK1.1, 2B4, and NKG2D (Figure 7E-F and
data not shown). Rroid-deficient liver CD49a+ ILC1s did not display a decrease in IFN-g
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production upon cytokine stimulation, indicating that in these cells, this regulatory region
is dispensable for cytokine production (Figure 7G).
To gain insight into the mechanism underlying this difference, we first established
the expression of the receptors for IL-12, IL-15, and IL-18 in splenic and liver NK cells. We
observed that expression IL-18 receptor (IL-18R) expression was unaltered, indicating that
loss of IL-18-dependent signals were unlikely to be the cause of this defect (Figure 8A).
Expression of CD122, a component of the IL-15 receptor in NK cells, was significantly
increased (Figure 8A). However, phosphorylation of STAT5 downstream of IL-15
signaling in splenic NK cells was unaltered, suggesting that activation through STAT5 was
also not impaired in Rroid-/- NK cells (Figure 8B). Expression of Il12rb2, encoding a
component of the IL-12 receptor, was reduced in NK cells from Rroid-/- mice as compared
to WT mice (Figure 8C-D). Activation of the IL-12 receptor induces downstream
phosphorylation of STAT4. This process was significantly decreased in Rroid-deficient NK
cells (Figure 8E). However, in accordance with the absence of a reduction in IFN-g
production in Rroid-/- ILC1s, Il12rb2 expression and p-STAT4 accumulation in response to
IL-12 stimulation was unaffected in liver ILC1s (Figure 8D&F). These results indicate that
the Rroid locus is required for NK cell function, in part through regulating responsiveness
to IL-12.

2.3.4 The Rroid locus regulates in vivo NK cell responses
We next sought to establish whether the defects observed ex vivo had significant
physiological consequences in vivo. We first determined the capability of Rroid-deficient
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NK cells to clear tumor cells in vivo using the RMA tumor cell line system; RMA-S tumor
cells are targeted by NK cell due to loss of MHC-I expression (Figure 9A). Indeed, we
found that Rroid-/- mice were significantly impaired in their ability to clear RMA-S tumor
cells (Figure 9B). In contrast to the protective effect of NK cells in clearing tumor cells,
NK1.1+ cells promote bacterial replication during systemic infection with Listeria
monocytogenes (Lm)137,138. Consistent with these data, Rroid-/- mice infected with Listeria
had significantly reduced bacterial loads in the spleen and liver 3 days post infection
(Figure 9C), and Rroid-/- NK cell and ILC1 populations in the spleen and liver remained
significantly reduced and produced less IFN-g than their wild-type counterparts (Figure
9D-E). These results indicate a central role for the Rroid locus in regulating the function of
NK cells in vivo and ex vivo.
ILC1s have been shown to provide protection against Salmonella Typhimurium
(STm) infection9. Consistent with a lack of defects in SI-LPL ILC1s in Rroid-deficient mice,
we did not detect significant differences in infection of the Peyer’s patches, dissemination
to the mesenteric lymph node (MLN) or spleen as well as in the recruitment of myeloid
cells 5 days post STm infection (Figure 9F). Furthermore, Rroid-/- NK cells expressed
reduced amounts of IFN-g, whereas IFN-g production in ILC1s was unchanged (Figure
9G). These results indicate that the Rroid locus does not impact ILC1 function in the gut
or MLN in vivo.
As group 1 ILCs are closely related to ILC2s and ILC3s, and are often functionally
regulated by similar pathways, we asked whether ILC2 and ILC3 responses are altered in
the absence of the Rroid locus. We tested the in vivo function of Rroid-/- ILC2s using the
papain lung inflammation model, where recruitment of eosinophils to the bronchoalveolar
37

lavage (BAL) fluid and lung parenchyma is dependent on IL-5 production by ILC2s139. In
this setting, Rroid-/- mice treated with papain recruited similar numbers of eosinophils as
compared to Rroid+/+ mice (Figure 10A). Moreover, Rroid-/- and wild-type ILC2s expressed
equivalent amounts of IL-5 and IL-13 (Figure 10B). These results indicate that Rroid is
not required for ILC2 responses in the lung.
In the gut, ILC3s mediate multiple processes including the induction of Peyer’s
patch organogenesis by the ILC3 subset lymphoid tissue inducer (LTi) cells. Rroid-/- mice
exhibited normal numbers of Peyer’s patches, indicating that LTi cells function normally in
the absence of the Rroid locus (Figure 10C). In inflammatory settings, the cytokines IL23 and IL-1b activate ILC3s to secrete IL-22. IL-22 production was unchanged in Rroid-/ILC3s, indicating that Rroid does not regulate cytokine production in ILC3s (Figure 10D).
Finally, as IFN-g production is regulated similarly in group 1 ILCs, CD4+ T cells and CD8+
T cells, we examined the production of this cytokine in these adaptive lymphocytes. We
found that production of IFN-g was unaltered in in vitro polarized CD4+ Th1 cells and
activated CD8+ T cells from Rroid-/- mice (Figure 10E-G), indicating that the Rroid locus is
dispensable for cytokine responses in activated T cells. Taken together, our results
indicate that the Rroid locus is specifically required for the homeostasis and function of
group 1 ILCs, but not ILC2s or ILC3s.
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2.4 Discussion
Appreciation for the roles lncRNAs play in the regulation of immune responses and
immune cell development is constantly growing. Induction of lncRNA transcription is now
known to regulate monocytes, macrophages, eosinophils, neutrophils, eosinophils,
dendritic cells, T cells, and B cells89,101,107,117,132,133. Although ILCs exhibit remarkable
diversity in both humans and mice, our understanding of how lncRNAs regulate ILCs is
still incomplete. Since the studies in this Chapter were undertaken only one other lncRNA,
lncKdm2b, has been described to regulate ILC3 homeostasis87.
In this Chapter, we hypothesized that high expression of lncRNAs might mark key
cis-regulatory elements in ILCs. Examination of published datasets79,80 revealed a number
of lncRNAs specifically expressed in the different ILC lineages. Among them, the lncRNA
Rroid was specifically and highly expressed in ILC1s, and located near the key ILC gene
Id2, indicating that this lncRNA might indeed mark a key cis-regulatory element. Genetic
ablation of the locus encoding Rroid using the CRISPR/Cas9 system resulted in
significantly reduced steady state numbers of NK cells in the spleen. Further examination
of immune cell populations in Rroid-deficient mice showed that 1) group 1 ILCs were
decreased in spleen, liver, lung, and intestinal epithelium; 2) in vitro NK cell function, but
not ILC1, ILC2, or ILC3 function was decreased in the absence of the Rroid locus; and 3)
Rroid-/- mice were less susceptible to Listeria infection, yet also displayed a reduction in
tumor cell rejection in vivo. The cellular and molecular mechanisms behind this phenotype
are the subject of studies detailed in Chapter 3. Altogether, these studies show that a cisregulatory element demarcated by the transcription of the lncRNA Rroid regulates the
homeostasis of group 1 ILCs in multiple tissues.
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Group 1 ILCs represent phenotypically diverse populations of cells found in many
tissues around the body, and the both the environmental and epigenetic factors regulating
these populations remains unclear. In our study, we found that loss of the Rroid locus
resulted in decreased NK cell numbers in all tissues examined. However, with ILC1s the
phenotype was more variable: ILC1s were dramatically reduced in the liver, lung, and
intestinal epithelium, but were unaffected in the lamina propria and salivary gland. The
reasons behind this difference are currently unclear. SG ILC1s are an unusual ILC1
population that share features of both NK cells and ILC1s, uniquely require TGF-b
signaling for their homeostasis, and develop in the absence of NFIL3, a transcription factor
required for the development of all other ILC subsets44,51,136,140-147. Indeed, although the
Rroid lncRNA itself is expressed in SG ILC1s, unique tissue-specific signals, such as TGFb, regulating the biology of SG ILC1s may compensate for the loss of the Rroid locus.
Therefore, detailed transcriptional and genetic analyses of Rroid-/- SG ILC1 will be required
to understand the regulation of these cells in the absence of Rroid.
Similarly, we also failed to find differences in SI-LPL ILC3 populations. This finding
could arise because like SG ILC1s, SI-LPL ILC1s are unique in that an appreciable
proportion of this ILC1 population arise from Rorgt+ ILC3s due to plasticity of ILC3s in this
tissue9,75. Previous studies suggest that the ILC3®ILC1 conversion in the small intestine
can be driven by the actions of IL-12, IL-18, and IL-1b9,148. Proliferation of “exILC3” ILC1
cells is also supported by IL-15 in the small intestine75. Thus, it is possible that exILC3
ILC1s may mask the loss of “natural” ILC1s in the SI-LPL. More complex genetic tools will
therefore be required to determine the relative contribution of exILC3s in the SI-LPL ILC1
compartment of Rroid-/- mice. Future studies will require the generation of Rorccre
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Rosa26LSL-tdTomato Rroid-/- mice and controls to simultaneously identify Rorgt+ ILC3s, RorgttdTomato+ exILC3, and Rorgt- tdTomato- ILC1s in order to assess the contribution of
exILC3s to the small intestine ILC1 compartment of Rroid-deficient mice.
In this study, we show that a lncRNA regulates the function of NK cells, but not
ILC1, ILC2, or ILC3 populations. The cytokines IL-12, IL-15 and/or IL-18 synergize to
induce robust IFN-g production in NK, a response that was significantly reduced in Rroid/-

NK cells in the liver and spleen. Interestingly, while these cytokines have similarly been

shown to induce IFN-g production in liver ILC1s, we did not observe any defects in cytokine
production in these cells. Examination of cytokine receptor expression in these cells
showed that while IL-18R1 expression was unchanged, expression of the beta 2 subunit
of the IL-12 receptor (Il12rb2), which forms a complex with IL-12Rb1 to act as the
functional IL-12 receptor, was significantly reduced in Rroid-/- NK cells. Indeed, STAT4
phosphorylation downstream of IL-12 stimulation was reduced in NK cells, but not ILC1s.
The reasons for these differences are not currently clear but may have to do with the
specific molecular mechanisms through which the Rroid locus works in group 1 ILCs.
Moreover, activation of NK cells through crosslinking of receptors such as NK1.1, NKG2D,
and CD244, which signal through distinct pathways from IL-12, resulted in significantly
reduced IFN-g production and degranulation. This indicates a more generalized loss of
effector function of Rroid-/- NK cells. Indeed, our in vivo experiments showed reduced NK
cell responses to Listeria and failure to eliminate tumor cells upon challenge.
In summary, the results presented in this study add to the growing body of literature
which implicate transcription of long-noncoding RNAs as a key regulatory layer in immune
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cell development and effector responses. We found that lncRNAs are specifically
expressed in each ILC lineage, implying that they might be key regulators of ILC
homeostasis and function. Thus, further studies will be required to dissect the different
pathways regulated by lncRNAs in ILCs.
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2.5 Figures

Figure 4: Rroid is a lncRNA expressed in group 1 ILCs
(A) Heatmap of lncRNAs specifically expressed in ILCs sorted from small intestine.
(B) Gene browser tracks of ATAC-seq (top) and RNA-seq (bottom) from indicated cell
populations.
(C) Rroid expression in indicated mouse tissues was determined by quantitative PCR
(qPCR). Normalized to Hprt expression. (n=3). Data are representative of two
independent experiments.
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(D) Rroid expression by qPCR in sorted cell populations from spleen, liver (Lv), small
intestine lamina propria (SI), and lung parenchyma (n=3; liver populations represent
n=2 of 5 pooled mice each). Normalized to Hprt expression. Data are pooled from
multiple independent experiments.
(E) Model of Rroid locus and CRISPR/Cas9 targeting strategy. Rroid is an ~2kb
transcript encoded from a locus covering ~70kb on mouse chromosome 12.
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Figure 5: The Rroid locus controls group 1 ILC homeostasis
(A) Representative flow cytometry plots of NK1.1+ NKp46+ cells in Rroid+/+ and Rroid-/mice isolated from lung tissue. (Gated on live, CD45.2+ CD3,CD5- cells).
(B) Absolute numbers of CD3,CD5- NK1.1+ NKp46+ cells in indicated mouse tissues
(n=4). Data are representative of three independent experiments.
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(C) Gating strategy to identify CD49a+ ILC1s and CD49b+ NK cells in mouse liver. Cells
were pre-gated on CD45.2+ CD3,CD5- cells.
(D) Absolute numbers of liver and lung NK cells and ILC1s (right; n=4). Data are
representative of three independent experiments.
(E) Absolute numbers of Lin- CD45.2+ CD90.2+ Rorgt- Eomes- T-bet+ ILC1s in the small
intestine intraepithelial lymphocyte (IEL) and lamina propria (SI-LPL) compartments
(left) and salivary gland CD3,CD5- CD45.2+ CD49b+ CD49a+ ILC1s (right). (n=3-4).
Data are representative of two to three independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 6: The Rroid locus is dispensable for ILC2s and ILC3s
(A) Flow cytometry plots depicting gating strategy of splenic immune cell populations.
(B) Absolute numbers of splenic leukocyte populations (n=4). Data are representative of
two independent experiments.
(C) Flow cytometry plots showing ILC2 and ILC3 gating in the small intestine. Cells were
pre-gated on live CD3, CD5, CD19- CD45.2+ CD90.2+ cells. ILC2s are GATA-3+;
ILC3s are Rorgt+.
(D) ILC2 gating strategy in the lung. Cells were pre-gated on Lin(CD3, CD5, CD11b,
CD11c, CD19, NK1.1)- CD45.2+ cells.
(E) Absolute numbers of ILC2 and ILC3 populations from indicated tissues (n=3-5).
Intestinal ILC2s were Lin- CD45.2+ CD90.2+ GATA3+ Rorgt-; ILC3s were Lin- CD45.2+
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CD90.2+ GATA3- Rorgt+. Lung ILC2 were Lin- CD45.2+ CD90.2+ T1/ST2+. Data are
representative of three independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 7: The Rroid locus is necessary to NK cell function
(A) Flow cytometry plots depicting IFN-g production by splenic NK cells. Splenocytes
were stimulated 4h ex vivo with a combination of 20ng/mL IL-12 and 20ng/mL IL-18.
(B) Quantification of IFN-g production in splenic NK cells stimulated as in (A). Data are
representative of three independent experiments.
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(C) NK cell degranulation as measured by CD107a staining in splenocytes activated by
anti-NK1.1 for 4h ex vivo.
(D) Quantification of NK cell degranulation as in (C). Data are representative of two
independent experiments.
(E) qPCR analysis showing expression of Perforin (encoded by Prf1) in sorted splenic
NK cells.
(F) Representative flow cytometric histogram of Granzyme B (GzmB) in splenic NK cells
(left) and proportion of GzmB+ NK cells (right).
(G) IFN-g production in liver NK cells (left) or ILC1s (right). Liver lymphocytes were
stimulated for 4h ex vivo with 20ng/mL IL-12, a combination of IL-12 and 20ng/mL IL15/IL-15Ra complex, or media alone (n=3-4). Data are representative of two
independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 8: Loss of the Rroid locus impairs IL-12 signaling in NK cells
(A) Representative flow cytometric histograms of IL-18Ra (left) and CD122 (right).
Average GMFI±SEM is indicated on the histogram (n=3-4). Data are representative
of three independent experiments.
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(B) Phosphorylation of STAT5 in response to stimulation by IL-15/IL-15Ra complexes.
Splenocytes were stimulated for 1h in serial 10-fold dilutions of IL-15/IL-15Ra
ranging from 100ng/mL to 0.003ng/mL. Data are presented as percent of MFI in
100ng/mL condition (n=3). Data are representative of two independent experiments.
(C) Expression of Il12rb1 and Il12rb2 measured by qPCR in sorted splenic NK cells
(n=4).
(D) Expression of Il12rb2 by qPCR in liver NK cells and ILC1s. 2500 NK cells and ILC1s
were sorted from the liver and subjected to 1-step qRT-PCR. Data are normalized to
Hprt1 expression. (n=3).
(E) Phosphorylation of STAT4 in response to IL-12. Shown is GMFI of p-STAT4 in
response to IL-12 at the indicated time points (left) and frequency of p-STAT4+
splenic NK cells (right) 20 minutes after stimulation.
(F) Phosphorylation of STAT4 in response to IL-12 in liver ILC1s (n=4).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 9: The Rroid locus regulates NK responses in vivo
(A) Experimental outline of the RMA-S transfer system to probe NK cell function in vivo.
5x106 CFSE-labeled RMA cells (MHC-I+) and 15x106 CTV-labeled RMA-S (MHC-I-)
were combined and injected intravenously into recipients, and splenocytes were
analyzed 16h after injection.
(B) Gating strategy for identifying fluorescently-labeled RMA and RMA-S cells in the
spleen (left). Ratio of RMA-S:RMA cell numbers (right, n=6 mice from two pooled
independent experiments).
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(C) Listeria monocytogenes (Lm) burden in the liver (left) and spleen (right). Mice were
infected intravenously with 3x104 CFU of Listeria and analyzed 3d post infection
(n=8-9). Data are representative of two independent experiments.
(D) Absolute numbers of ILC1 (left) and NK cells (right) in the livers of Rroid-/- mice and
controls 3d post infection with Listeria (n=4-5).
(E) Production of IFN-g from splenic NK cells in mice 3d post infection with Listeria. Cells
were stimulated 4h with 20ng/mL IL-12, a combination of IL-12 and 20ng/mL IL-18,
or with media alone. (n=4-5).
(F) CFU of Salmonella Typhimurium (STm) in Peyer’s patches, mesenteric lymph nodes
(MLN), and spleens of mice 5d post infection (n=10). Data are pooled from two
experiments.
(G) Frequency of IFN-g+ NK cells (left) and ILC1 (right) in the MLN of mice 5d post
infection with STm. (n=10). Data are pooled from two experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 10: ILC2 and ILC3 function does not require the Rroid locus
(A) Absolute numbers of eosinophils (CD45+ CD11c- Siglec-F+) in the bronchoalveolar
lavage (BAL) and lung parenchyma of mice challenged intranasally with 30µg papain
every 24h for 5 days (n=4-5).
(B) ILC2 cytokine production from mice challenged with papain. Lung lymphocytes were
stimulated 4h with PMA/Ionomycin and gated on CD45+ CD3,CD5,CD19- CD90.2+
T1/ST2+ cells (n=5).
(C) Enumeration of Peyer’s patches in the small intestine of Rroid+/+ and Rroid-/- mice
(n=10 pooled from three independent experiments).
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(D) IL-22 production in small intestine ILC3s. Lymphocytes from small intestine were
stimulated 4h with media alone (U/S), IL-23 (20ng/mL), or IL-23 and IL-1b (10ng/mL)
(n=4). Representative of two independent experiments.
(E) Representative flow cytometry plots of CD4+ T cells cultured in Th0 and Th1
polarizing conditions. Cells were restimulated 4h with PMA/Ionomycin.
(F) Frequency of IFN-g+ CD4+ T cells cultured in Th0 or Th1 conditions. (n=3). Data are
representative of two experiments.
(G) Frequency of IFN-g+ CD8+ T cells cultured for 3d with or without anti-CD3/anti-CD28.
(n=3). Data are representative of two experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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CHAPTER 3: The Rroid locus regulates group 1 ILC maturation and lineage
identity through Id2

3.1 Abstract
Long non-coding RNAs are widely expressed in the immune system, and many recent
studies have shown that lncRNAs play crucial roles in regulating epigenetic and
transcriptional responses in immune cells. In Chapter 2, we showed that lncRNAs were
specifically expressed in each ILC lineage, suggesting they may play key roles in
regulating the development or effector responses of these cells. Thus, we deleted the
locus encoding one such lncRNA expressed in group 1 ILCs, which we called Rroid. We
found that this lncRNA controlled the steady state numbers and effector functions of these
cells. In Chapter 3, we show that the Rroid locus does not regulate the commitment of
group 1 ILCs to the ILC lineage, but rather promotes the proliferation and survival of
mature group 1 ILCs by promoting expression of Id2. A key transcriptional repressor in
ILCs, Id2 is required to inhibit the activity of E-proteins, which activate expression of
adaptive lymphocyte genes. In the absence of Rroid, and thus Id2, we find that adaptive
lymphocyte genes are aberrantly expressed in group 1 ILCs. Finally, we find that this
phenotype can be reversed through ectopic expression of Id2 in Rroid-/- NK cells.
Altogether, these data show that the Rroid locus promotes group 1 ILCs by promoting their
lineage identity by regulating Id2 expression.
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3.2 Introduction
All ILCs are thought to derive from common precursors, with the earliest known
precursors giving rise to all ILC subsets being early ILC progenitors (EILP)34. A second
related population of integrin a4b7+ lymphoid precursor (aLP) cells that are capable of
giving rise to all ILC subsets were also identified, although subsequent single cell analyses
revealed that this precursor population contains cells marked by ILC lineage-defining
genes such as Rorc (Rorgt), suggesting that the aLP population contains committed
ILCs44,45,149. Natural Killer cells branch off from the rest of the helper-like ILCs after the
EILP stage, as they derive from NK cell precursors (NKPs), while ILC1s, ILC2s, and ILC3s
are derived from the common helper ILC precursors (CHILPs)46,50,150.
A key step in the commitment of these progenitors to the ILC fate is induction of
the transcriptional repressor Id2. Expression of Id2 first occurs in EILPs and is highly
expressed in both CHILPs and NKPs. Induction of Id2 is critical for the development of
these cells, as mice deficient in Id2 have reduced EILPs, no CHILPs, and no mature ILCs
in the periphery7,34,40,47,135,151. Id2 is not required for the generation of NKPs or immature
NK cells in mice, as these populations still develop in Id2-/- mice47. Instead, early absence
of Id2 in these cells seems to be compensated for induction of the related gene Id347.
Nonetheless, Id2 is required for the maturation of NK cells, as Id2-/- NK cells fail to
upregulate maturation markers47,48,54,55. In addition to its key roles in promoting the
development and maturation of ILCs, Id2 is also required in fully mature ILCs to both
maintain their numbers and to promote appropriate effector responses, as NK cells and
ILC3s in which Id2 is inducibly depleted through cre-mediated deletion exhibit defects in
number and function55,152.
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Id2 is related to E-box transcription factors, which are basic helix-loop-helix (bHLH)
transcription factors that regulate key genes involved in T and B cell development151. Eproteins, such as E2A, E2-2, and HEB (encoded by Tcf3, Tcf4, and Tcf12, respectively)
form either homo- or heterodimers with other E-proteins in order to form an active unit that
binds to DNA to activate transcription of target genes151. In contrast, Id2 can form
heterodimers with E-proteins, but because Id2 lacks a basic DNA-binding domain the
resulting heterodimers are unable to bind target sequences to activate transcription151.
Negative regulation of E-proteins is thought to be the primary mechanism through which
Id2 promotes ILC development and function, given that overexpression of Id2 in
thymocytes blocks T cell development while promoting NK cells and ILCs153-155.
Despite the importance of Id2 in promoting the homeostasis and function of ILCs,
very little is known about how its expression is regulated in these cells. As described
above, Id2 is not transcribed in CLPs but is robustly induced from committed ILC
progenitors to mature ILC populations. The signals inducing its expression in precursors
and maintaining its expression in mature cells are not known. However, previous studies
have implicated additional key ILC transcription factors in the regulation of Id2 expression
in ILCs. For example, the transcription factors NFIL3, ETS1, and TOX have all been
demonstrated to promote Id2 expression in ILCs51,156,157. In addition, STAT5-mediated
signals have been implicated in induction of Id2 expression in CD8a+ DCs, which is
required for their development158. This implies that similar signals may induce Id2
expression in ILC1s, as these cells also rely on STAT5 induction downstream of IL-15
receptor signaling.
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In Chapter 2, we showed that lncRNA expressed in group 1 ILCs could regulate
their homeostasis and effector functions, but the mechanisms through which this occur
remained unclear. In this Chapter, we investigated whether the Rroid locus might control
group 1 ILC homeostasis through regulation of the Id2 locus.
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3.3 Results
3.3.1 The Rroid locus is required for the maturation of NK cells
Because the Rroid locus controls the frequency and function of group 1 ILCs, we
next sought to examine whether it is necessary for initial commitment to the NK cell and
ILC1 lineages, their development, or maturation. Using Rroid RNA expression as a proxy
for activity at this locus, we found that Rroid was not expressed in bone marrow lymphoidprimed multipotent progenitor (LMPP) cells or CLPs, which give rise to both ILCs and
adaptive lymphocytes (Figure 11A). Consistent with this, we also failed to find differences
in the numbers of bone marrow LMPPs and CLPs (Figure 11B-C).
NK cells are derived from NK cell progenitors (NKP), which can be divided into
pre-NKP (pNKP) and refined-NKP (rNKP), identified by defined cell surface markers
(Figure 11B)150. Surprisingly, we did not observe any differences in in bone marrow NKPs
between Rroid-/- and their wild-type counterparts (Figure 11C). In addition to NKPs, these
populations also contain small numbers of cells marked by expression of Zbtb16 (also
called PLZF), that are progenitors of helper ILCs, including ILC1s46,50. We did not observe
any defects in NK cell (pNKP, rNKP) or ILC (PLZF+ pNKP/rNKP) progenitors in Rroid-/mice (Figure 12A), nor did we observe alterations in common helper ILC precursors
(CHILPs)(Figure 12B). Finally, the bone marrow NK cells and ILC1 populations were also
unaffected (Figure 12C). Altogether, these results indicate that the Rroid locus is not
required for group 1 ILC lineage commitment or their early development.
We then assessed the processes regulated by the Rroid locus in peripheral group
1 ILC populations. Following the production of new NK cells in the bone marrow, immature
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NK cells undergo a maturation process driven by the cytokine IL-15, which is characterized
by the acquisition of the surface marker CD11b, loss of CD27, and increased proliferation
and survival (Figure 13A)54,159. Ablation of the Rroid locus resulted in a block of NK cell
maturation characterized by accumulation of immature CD27+ NK cells and a near
complete loss of mature CD11b+ NK cells (Figure 13B). This block in maturation was
accompanied by impairment in the proliferation and survival capacity of maturing Rroid-/NK cells as determined by BrdU incorporation and Annexin V staining (Figure 13C).
Finally, to verify that the Rroid locus regulates NK cells in a cell-intrinsic manner,
we generated mixed bone marrow chimeras with Rroid-/- and congenically-marked wildtype bone marrow (Figure 14A). We found that Rroid-deficient NK cells retained
significant defects in maturation and cytokine production in mixed bone marrow chimeras,
indicating that the Rroid locus controls NK cell function and maturation in a cell-intrinsic
manner (Figure 14B-D). Altogether, these data indicate that the Rroid locus regulates
group 1 ILC populations by promoting their maturation, proliferation, and survival.

3.3.2 The Rroid locus promotes Id2 expression
Our findings reveal a critical role for the Rroid locus in the homeostasis, maturation,
and function of group 1 ILCs. Cis-regulatory elements and lncRNAs can control the
expression of neighboring genes101,107,160,161, but lncRNAs are also known to act in trans
to regulate gene expression programs99,117,120,130. Therefore, to identify the regulatory
functions of the Rroid locus in group 1 ILCs through an unbiased approach that accounts
for both possibilities, we performed RNA-seq on sort-purified splenic DP (CD27+ CD11b+)
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NK cells. Among 58 significantly differentially expressed transcripts, the canonical ILC
gene, Id2, was reduced in these cells (Figure 15A). Similarly, splenic and liver NK cells
as well as liver ILC1s from Rroid-/- mice showed decreased levels of Id2, while key
transcription factors required for their normal development (Ets1, Tox, Nfil3, T-bet, and
Eomes) were unaltered (Figure 15B-C and data not shown). In accordance with Rroid’s
pattern of expression and the lack of defects in the frequency and function of ILC2 and
ILC3 populations in Rroid-deficient mice, Id2 expression was not dysregulated in sorted
small intestine ILC3s or IL-33 elicited lung ILC2s from Rroid-/- animals, nor it was altered
in in vitro polarized Th1 cells or activated CD8+ T cells (Figure 15D). These results indicate
that the Rroid locus is promotes Id2 expression specifically in peripheral group 1 ILCs.

3.3.3 Loss of Id2 expression in Rroid-/- NK cells results in increased expression of
adaptive lymphocyte genes
Id2 expression is required for commitment to the ILC lineage during early
development in the BM and maintains the identity of mature ILCs by directly antagonizing
E-protein transcription factors, which are critical for promoting T and B cell lineage-specific
gene expression programs135,151. Therefore, we sought to establish whether Rroidmediated regulation of Id2 in group 1 ILCs is required to prevent the aberrant expression
of genes classically associated with adaptive lymphocytes in group 1 ILCs. Gene set
enrichment analysis (GSEA) confirmed a significant enrichment of known Id2-dependent
genes in our RNA-seq dataset (Figure 16A)55. Furthermore, expression of T and B cell
specific genes (e.g. Cd3d, CD3g) and the E-protein target Tcf7 were all significantly
increased in NK cells deficient for the Rroid locus (Figure 15A and 16B-C). These data
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imply that E-protein mediated transcriptional activation of adaptive lymphocyte genes is
increased in Rroid-/- NK cells. To address this possibility, we mapped genome-wide open
chromatin using ATAC-seq and performed transcription factor footprinting analysis to
determine whether canonical E-protein binding sites were enriched in Rroid-/- NK cells.
This analysis revealed enrichment of binding sites for E2A and E2-2 (encoded by Tcf3
and Tcf4, respectively) within the 2837 open chromatin peaks specific to Rroid-deficient
NK cells (Figure 16D-E). Furthermore, both binding sites and expression of the E-protein
target Tcf755,162 were also enriched in regions of open chromatin specific to Rroid-/- NK
cells (Figure 16E). Consistent with our previous finding indicating that adaptive
lymphocyte genes are derepressed in the absence of the Rroid locus, open chromatin
peaks in Rroid-/- NK cells were significantly associated with genes in the T and B cell
receptor signaling pathways (Figure 16F). Together, these results suggest that the Rroid
locus maintains group 1 ILC lineage identity by promoting Id2-mediated repression of Eprotein target genes.
Finally, to formally determine whether downregulation of Id2 in Rroid-deficient
group 1 ILCs is the key alteration impairing their identity, maturation, and function, we
reconstituted lethally irradiated hosts with Rroid-/- bone marrow transduced with a
retrovirus encoding Id2 (Figure 17A). Restoring Id2 expression in Rroid-/- bone marrow
cells resulted in increased peripheral NK cell populations and a reversal of their maturation
defects (Figure 17B-C). Altogether, these data indicate that the Rroid locus promotes
peripheral group 1 ILC homeostasis and maturation primarily through its role in regulating
Id2 expression.
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3.4 Discussion
Despite the key role that Id2 plays in promoting ILCs, very little is known about
how its expression is regulated in these cells. In Chapter 2, we hypothesized that the
Rroid lncRNA locus might regulate group 1 ILCs based partially on its proximity to Id2 in
the genome. In this chapter, we tested whether this was the case. We found that 1) the
Rroid locus specifically promoted group 1 ILC maturation through Id2 expression in group
1 ILCs; 2) that loss of Id2 resulted in aberrant expression of adaptive lymphocyte genes
in Rroid-/- NK cells; and 3) that ectopic expression of Id2 in Rroid-/- hematopoietic cells
reversed the group 1 ILC maturation defect.
Previous studies in Id2-/- mice have shown that expression of this gene is required
for the generation of all ILC progenitor populations7. In concordance with the known
requirement for Id2 in ILC1 and NK cell homeostasis41,47,48, we found that the maturation
of NK cells was significantly impacted by loss of the Rroid locus. Also consistent with the
lack of any observable defects in ILC2 and ILC3 populations in Chapter 2, deletion of the
Rroid locus did not affect the numbers of CHILPs or ILC precursors (ILC1p) marked by
expression of PLZF46,50. However, while we observed induction of Rroid transcription at
the NKP stage, we did not observe any reduction in the number of NKPs, ILC1 precursors,
or immature group 1 ILCs in the bone marrow of Rroid-/- mice.
It remains unclear why we did not observe defects in the generation of NK and
ILC1 precursors despite high expression of Rroid in NKP and, presumably, ILC1p. As it is
not known whether Id2 expression is impacted in Rroid-/- NKP and ILC1p cells, one
possibility is that while Rroid is required for appropriate Id2 expression in mature group 1
ILCs, other cis-regulatory elements may promote Id2 expression in their progenitors.
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Another possibility is compensation by other members of the Id family. Indeed, Id3 is coexpressed alongside Id2 in NKP and is upregulated in Id2-/- NKPs, potentially
compensating for the loss of Id247,48. Whether this axis compensates for the loss of Id2 in
Rroid-/- mice requires future study. Additionally, the role of Id3 in ILC1 development and
homeostasis has not been addressed. As Id2-/- mice lack all mature peripheral ILCs as
well as their progenitors, it seems unlikely that Id3 can compensate for loss of Id2 in this
context. Further studies will need to be directed at teasing apart the contributions of each
pathway in group 1 ILC development in the absence of the Rroid locus.
The biological function of Id2 in ILCs is thought to be mediated through inhibition
of E-protein transcription factors such as E2A, E2-2, and HEB in order to promote their
lineage commitment151. In our study, we found both enrichment of E-protein binding sites
in regions of open chromatin specific to Rroid-/- NK cells, as well as significantly increased
expression of an E-protein target gene Tcf7. This was also associated with a reduction in
proliferation of immature NK cells, and increased cell death in mature NK cells. Together,
these data suggest that in the absence of the Rroid locus, and thus Id2, E-protein activity
in group 1 ILCs is dysregulated, leading to decreased proliferation and increased
apoptosis of the cells. Since the publication of this study, Zook et al.48 reported similar
results, including reduced proliferation and upregulation of E-protein targets such as Tcf7,
as well as T cell receptor signaling components.
Simultaneously, Miyazaki, et al.155 showed that E2A and HEB, respectively
suppress the development of ILC precursors in the thymus. Interestingly, ILCs express
low but detectable levels of E-protein expression in RNA-seq datasets (data not
shown)79,80. Along with our study, these data suggest that ILCs require Id2 to keep E66

protein activity in check both during their development and maturation. However, whether
low level E-protein expression plays any role in ILC development, maturation, or function
requires future study.
Altogether, the data presented in this Chapter support a model wherein induction
or maintenance of Id2 expression in ILC1 and NK cells, and thus their development,
maturation, and effector function, is dependent on the Rroid locus. Indeed, we found that
ectopic expression of Id2 in bone marrow precursors rescued peripheral group 1 ILC
numbers and maturation. It is important to note that this treatment did not fully rescue NK
cell maturation and cytokine production defects. This could yet reflect differences in Id2
expression between wild type, Rroid-/-, and Rroid-/- + Id2 rescue NK cells. Additionally, it
could reflect functions for the Rroid locus beyond the regulation of Id2. Further study will
be required to interrogate these different possibilities.
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3.5 Figures

Figure 11: Early NK cell development is not affected in Rroid-/- mice
(A) Rroid expression in NK cells and progenitors. Lymphoid-primed multipotent
progenitors (LMPP), common lymphoid progenitors (CLP), and NK cell progenitors
(NKP) sorted from bone marrow; CD27+, double positive (DP, CD27+, CD11b+), and
CD11b+ NK cells sorted from spleen and Rroid expression was quantified by qPCR
(LMPP, CLP, and NKP populations are n=2 of 5 pooled mice each, and splenic NK
cells are n=3). Normalized to Hprt expression.
(B) Flow cytometry plots showing gating strategy for identifying LMPP, CLP, rNKP, and
pNKP cell populations in the bone marrow.
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(C) Absolute numbers of LMPP, CLP, pre-NK progenitor (pNKP), and refined NK
progenitor (rNKP) populations in bone marrow (n=3). Data are representative of two
independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 12: The Rroid locus is not required for early NK cell and ILC1 development.
(A) Histogram depicting the frequency±SEM of ILC progenitors marked by PLZF
expression in CLP, pNKP, and rNKP populations (left), and absolute numbers of
PLZF+ cells within pNKP and rNKP subsets (right). Shaded histograms are GFPnegative controls (n=3-4 mice per group from two pooled experiments).
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(B) Gating strategy for identifying common helper ILC progenitors (CHILP) in the bone
marrow (left). Absolute numbers of CHILP in Rroid+/+ and Rroid-/- mice (right; n=4).
Representative of two independent experiments.
(C) Absolute numbers of bone marrow NK cells and ILC1s (n=3). Data are
representative of three independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 13: group 1 ILC maturation is impaired in the absence of the Rroid locus
(A) Schematic (left) and flow plots (right) depicting maturation pathway in splenic NK
cells in Rroid+/+ and Rroid-/- mice. Gated on CD45.2+ CD3,CD5- NK1.1+ NKp46+ cells.
(B) Frequency (left) and absolute numbers (right) of NK cell maturation in the spleen of
Rroid+/+ and Rroid-/- mice (n=4). Data are representative of four independent
experiments.
(C) BrdU incorporation (left) and Annexin V staining (right) of maturing splenic NK cells.
Mice were injected i.p. every 12h with 1mg BrdU for 3d. Splenocytes were either
fixed and probed for BrdU incorporation or stained with Annexin V to determine cell
viability (n=3-4). Data are representative of two independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 14: Defects in maturation and cytokine production in Rroid-/- NK cells are cell
intrinsic
(A) Schematic of competitive bone marrow chimeras. We mixed CD45.2+ Rroid-/- bone
marrow cells 1:1 with CD45.1+ CD45.2+ Rroid+/+ bone marrow and reconstituted
lethally-irradiated CD45.1+ hosts. Splenocytes were analyzed 8 weeks post-transfer.
(B) Flow cytometry plot of maturing splenic NK cells in competitive bone marrow
chimeras analyzed 8 weeks post-transfer.
(C) Frequency of maturing splenic NK cells in competitive bone marrow chimeras (n=8).
Data are pooled from two independent experiments.
(D) IFN-g production in splenic NK cell populations from competitive bone marrow
chimeras (n=4). Data are representative of two independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 15: The Rroid locus regulates Id2 in group 1 ILCs
(A) Volcano plot of RNA-seq results in sorted splenic DP (CD27+, CD11b+) Rroid+/+ and
Rroid-/- NK cells. Genes with FDR<0.05 are depicted in blue (n=3).
(B) Id2 expression in maturing NK cell populations sorted from spleen and analyzed by
qPCR (n=3). Normalized to Hprt expression. Data are representative of two
independent experiments.
(C) qPCR of Id2 expression in sorted liver NK cells and ILC1s (n=2 of 5 pooled ).
Normalized to Hprt expression.
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(D) Id2 expression in sorted ILC3s from small intestine (left) or IL-33 expanded ILC2s
from lung (right) analyzed by qPCR (For ILC3s, n=4 pooled from two experiments;
for ILC2s, n=5 from one experiment). ILC2s were expanded by intranasal
administration of 250ng IL-33 daily for 4 days and sorted 24 hours following the last
injection. Normalized to Hprt expression.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.

75

Figure 16: Rroid-/- NK cells display increased adaptive lymphocyte genes and
increased E-protein activity
(A) Gene Set Enrichment Analysis (GSEA) depicting enrichment of known Id2-regulated
genes in Rroid-/- NK cells.
(B) GSEA depicting enrichment of KEGG T cell receptor signaling pathway genes in
Rroid-/- NK cells.
(C) Fold change in Tcf7 expression by qPCR in sorted splenic NK cells (n=4).
Normalized to Hprt expression and shown as fold change relative to controls. Data
are representative of two independent experiments.
(D) Venn diagram depicting unique ATAC-seq peaks called in sorted splenic Rroid+/+ and
Rroid-/- NK cells (n=3).
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(E) Heatmap of transcription factor footprinting analysis. Rroid+/+ and Rroid-/--specific
ATAC-seq peaks were subjected to transcription factor footprinting analysis by the
Protein Interaction Quantitation (PIQ) algorithm.
(F) Enrichment of cellular pathways associated with open chromatin elements in Rroid+/+
and Rroid-/- NK cells.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 17: Ectopic expression of Id2 rescues NK cell maturation in Rroid-/- NK cells
(A) Schematic of Id2 transduction experiment. Rroid-/- bone marrow was transduced in
vitro with retrovirus bearing Id2 or empty vector control and used to reconstitute
lethally irradiated CD45.1+ hosts. Transduced cells were identified by expression of
GFP.
(B) NK cells as a proportion of GFP+ cells in bone marrow chimeras reconstituted with
either empty retrovirus or Id2 retrovirus (n=4).
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(C) Frequency of maturing splenic NK cells in bone marrow chimeras reconstituted with
either empty retrovirus or Id2 retrovirus (n=4).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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CHAPTER 4: The Rroid locus promotes chromatin accessibility and STAT5
deposition at the Id2 promoter in group 1 ILCs

4.1 Abstract
In previous Chapters, we showed that lncRNAs are highly and specifically expressed in
subpopulations of ILCs. In particular, one lncRNA which we named Rroid was expressed
specifically in group 1 ILCs. In Chapter 2, we showed that genetic deletion of the ~80kb
Rroid locus in mice severely impacted group 1 ILC homeostasis, leading to significantly
reduced numbers of these cells and a significant reduction in NK cell function. In Chapter
3, we showed that the Rroid locus regulated was responsible for promoting expression of
the key ILC gene Id2 in ILC1s and NK cells, but not ILC2s or ILC3s. However, the
molecular mechanisms and whether the Rroid lncRNA itself directly mediates Id2
expression is still not clear. In Chapter 4, we show that the Rroid locus promotes
chromatin accessibility and STAT5 accumulation at the Id2 promoter in response to IL-15.
We show that this process did not require the Rroid lncRNA but could be partially
recapitulated by deletion of a group 1 ILC-specific regulatory element embedded within
the Rroid locus. Altogether, our data shows that Rroid expression marks critical regulatory
elements for controlling Id2 expression in group 1 ILCs.

80

4.2 Introduction
In Chapter 2, we showed that the Rroid locus controls group 1 ILC homeostasis
and function. In Chapter 3, we found that the Rroid locus controlled Id2 expression in
group 1 ILCs to promote the maturation of group 1 ILCs. However, the mechanisms
through which this lncRNA locus regulated Id2 expression were unknown. In this Chapter,
we set out to address how the Rroid locus regulates Id2 expression in group 1 ILCs.
As described in Chapter 1 and in Chapter 3, Id2 is a key gene which controls ILC
homeostasis by decreasing the activity of E-proteins, which drive expression of adaptive
lymphocyte genes. However, the molecular and epigenetic mechanisms controlling Id2
expression in ILCs and other cell types is not known. In dendritic cell lines, STAT5
activation downstream of GM-CSF receptor signaling has been shown to mediate Id2
upregulation by directly binding canonical STAT5 binding sites in the promoter of Id2.
Group 1 ILCs require STAT5-dependent cytokine signals downstream of IL-15 for their
development and homeostasis7,52, and stimulation of NK cells with IL-15 in vitro is
sufficient to induce Id2, but whether the Rroid locus is required for this process, and
whether STAT5 directly regulates Id2 or Rroid expression in group 1 ILCs is not known.
Long non-coding RNAs have been shown to exert their effects through a large
number of molecular mechanisms (Figures 2 and 3). As described in Chapter 1, some
lncRNAs, such as lnc-DC, function in the cytosol to regulate protein-protein interactions99.
Others, such as Morrbid, lincRNA-Cox2, lincRNA-EPS, and lncKdm2b localize to the
nucleus where they interact with transcription factors or chromatin modifying complexes
to control target gene expression87,101,117,120. Emerging literature has also shown that
lncRNA loci can exhibit RNA-independent regulation of their target loci, as in the case of
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the Blustr locus, where the act of transcription through the Blustr locus is a critical event
in promoting its target gene Sfmbt2107. At the same time, lncRNAs transcription can mark
key, active regulatory elements embedded within the lncRNA locus113,114.
In this Chapter, we sought to uncover the molecular mechanisms through which
the Rroid locus regulates Id2 expression in group 1 ILCs. In particular, we sought to 1)
determine whether the Rroid locus regulated chromatin accessibility and epigenetic marks
at the Id2 promoter; 2) test whether the key group 1 ILC cytokine IL-15 and its downstream
effector STAT5 regulated expression of Id2 and Rroid; and 3) test whether the Rroid locus
exerts its effects through an RNA-mediated mechanism, or whether an RNA-independent
mechanism promoted Id2 expression.

4.3 Results
4.3.1 The Rroid locus controls open chromatin and recruitment of STAT5 to the Id2
promoter
Both cis-regulatory elements and lncRNAs can regulate gene expression through
epigenetic mechanisms such as controlling chromatin accessibility and histone
modifications at the promoters of their target genes161. To determine whether the Rroid
locus regulates Id2 expression in group 1 ILCs through epigenetic mechanisms, we
performed ChIP-qPCR for histone modifications at the Id2 promoter in NK cells and
analyzed the Id2 locus in our ATAC-seq dataset. In the absence of the Rroid locus, histone
marks associated with active promoters (H3K27ac) and transcription (H3K36me3) were
significantly decreased at the Id2 promoter and gene body, respectively (Figure 18A-B).
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In accordance with these data, analysis of our ATAC-seq results also revealed decreased
chromatin accessibility within the Id2 promoter in Rroid-/- NK cells (Figure 19A-C). To
verify that deletion of the Rroid locus did not cause widespread changes to gene
expression and chromatin accessibility in other nearby genes, we examined both gene
expression and chromatin accessibility of genes within 1MB up- and downstream of Id2
and found that our results were specific to the Id2 locus (Figure 19D-E). Together, these
results indicate that proper chromatin accessibility and activating histone modification
levels at the Id2 promoter in NK cells require the Rroid locus.

4.3.2 The Rroid locus controls recruitment of STAT5 to the Id2 promoter
Among all ILCs, both NK cells and ILC1s are unique in that they require IL-15 for
their maturation, function, and homeostasis7. Furthermore, IL-15 has been previously
shown to induce Id2 expression in NK cells55. Thus, we next investigated whether the
Rroid locus is required for IL-15-mediated control of Id2 in group 1 ILCs. Using Rroid
transcription as a proxy for activity at the Rroid locus, we found that IL-15 induced both
Id2 and Rroid expression in NK cells in a dose-dependent manner (Figure 20A-B).
Moreover, IL-15 mediated induction of Id2 expression was dependent on the Rroid locus
(Figure 20C). Engagement of the IL-15 receptor directly activates downstream STAT5
signaling in group 1 ILCs. Thus, we next sought to establish whether STAT5 regulates Id2
expression through the Rroid locus. Using STAT5-deficient mice expressing only a single
allele of Stat5b (Stat5a-/- Stat5b+/-), we observed that STAT5 was required for NK cell
maturation as well as induction of Id2 transcription in NK cells in vivo (Figure 21A).
Additionally, in the absence of the Rroid locus, STAT5 occupancy was significantly
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decreased at the Id2 promoter (Figure 21C). Additionally, while the transcription factor Tbet (encoded by Tbx21) is known to be essential for the homeostasis of both NK cells and
ILC1s, we did not find a role for T-bet in the regulation of Id2 (Figure 22A-C). Altogether,
these results indicate that the Rroid locus is required for adequate STAT5 deposition at
the Id2 promoter in ILC1s, and thus critical for IL-15-mediated regulation of Id2 expression.

4.3.3 An ILC1-specific subdomain within the Rroid locus regulates NK cells
Our results indicate a critical role for the Rroid locus in promoting group 1 ILC
homeostasis through its regulation of Id2. Transcription of lncRNAs is known to mark
important regulatory regions but can also directly control gene expression results indicate
a critical role for the Rroid locus in promoting group 1 ILC homeostasis through its
regulation of Id2. Transcription of lncRNAs is known to mark important regulatory regions
but can also directly control gene expression89,101,107,161. Thus, to determine whether DNA
elements within the Rroid locus or the lncRNA itself regulate Id2 expression in NK cells,
we first utilized locked nucleic acids (LNAs) to decrease the levels of Rroid in cultured NK
cells in vitro (Figure 23A). Using this system, we observed a significant depletion of Rroid
RNA in wild-type NK cells electroporated with LNAs targeting Rroid (Figure 23B).
However, acute depletion of Rroid in mature NK cells ex vivo did not result in significant
changes in Id2 expression levels during the culture period (Figure 23C), indicating that
the Rroid lncRNA might not be required for the maintenance of Id2 expression in mature
NK cells.
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We next asked whether specific open chromatin sites within the Rroid locus unique
to ILC1 are required for Id2 expression or for the homeostasis and maturation of these
cells. Using ATAC-seq datasets for the different ILC populations, we identified two
elements within the Rroid locus that are uniquely open and accessible in ILC1s, which are
specifically localized in the promoter region and second intron of the Rroid lncRNA locus
(Figure 24A-C). Using chromatin conformation capture (3C), we found that these ILC1specific sites formed a long-range interaction with the Id2 promoter (Figure 25A). We also
examined STAT5 binding in this region via ChIP-seq and ChIP-qPCR and found that
STAT5 was recruited to these sites in response to IL-15 stimulation (Figure 25B-C).
To establish the role of these ILC1-specific open chromatin sites, we generated
mice lacking the promoter region and first exon of Rroid (Rroid-P1) or the putative
regulatory element in Rroid’s second intron (Rroid-RE1; Figure 24B-C). Deletion of RroidP1 did not affect the numbers of NK cells in the spleen (Figure 26A). Loss of Rroid-P1
also did not affect splenic NK maturation or Id2 expression (Figure 26B-E). Interestingly,
we did not observe a reduction in Rroid levels in either of these two new mouse strains
(Figure 26B), indicating that that Rroid has alternative transcriptional start sites. However,
Rroid-RE1-/- mice had a significantly lower proportion of mature NK cells and a reduction
in Id2 levels in these cells (Figure 26C-E), partially recapitulating the phenotype observed
in Rroid-/- mice. This indicates that while the RE1 cis-regulatory element contributes to the
regulation of Id2, it is likely that additional regulatory elements within the Rroid locus, or
potentially transcription across Rroid locus, are required for appropriate control of Id2
expression in group 1 ILCs in vivo.
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4.4 Discussion
Although Id2 is a key gene required for ILC homeostasis, very little is known about
how it is regulated at the transcriptional level in vivo, and whether epigenetic DNA
regulatory elements or lncRNAs play roles in this process. While we showed in previous
chapters that the lncRNA locus encoding Rroid was required for appropriate expression
of Id2 in group 1 ILCs, the molecular mechanisms through which Rroid controlled Id2 were
unclear. Specifically, whether the Rroid locus controlled epigenetic marks, chromatin
accessibility, or transcription factor binding to the Id2 promoter were not known.
Furthermore, whether the Rroid lncRNA itself directly activated Id2 expression or whether
DNA regulatory elements within the Rroid locus were required to promote Id2 expression
in these cells was not known. Thus, in this chapter we show that 1) the Rroid locus
regulates epigenetic marks and chromatin accessibility at the Id2 promoter in group 1
ILCs; 2) IL-15 stimulation induces STAT5 accumulation at the promoter of Id2, and the
Rroid locus is required for this process; and 3) the Rroid lncRNA does not play a direct
role in regulating Id2, but rather marks an important regulatory locus for controlling
expression of Id2 in group 1 ILCs.
Long non-coding RNAs have been described to work through a number of diverse
mechanisms. For example, lncRNAs can directly interact with protein factors, influencing
their acquisition of post-translational modifications such as phosphorylation, or by acting
as scaffolds for recruitment of epigenetic modifying enzymes. Other lncRNA loci are
known to exert their effects through different mechanisms, such as the transcriptiondependent or proxy signal models as described in Chapter 1 (Figure 2). In our study, we
found that the Rroid RNA did not directly promote Id2 expression in mature NK cells, as
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depletion of Rroid in cultured NK cells did not lead to loss of Id2. However, while we did
not observe a direct function of Rroid in regulating Id2 expression during acute depletion
using LNAs, we cannot rule out a role for the lncRNA in other contexts. For example,
expression of Rroid could be required for, or directly promote Id2 in the progenitors of NK
cells and ILC1s during their development. Alternatively, our in vitro knockdown using LNAs
may not have achieved a high enough level of depletion of Rroid to have an effect.
Notably, although we sought to ablate Rroid expression in vivo by generating Rroid-P1-/mice, we did not observe any reduction in Rroid in these mice. Thus, Rroid may be
transcribed from multiple transcriptional start sites. Additional in vivo models utilizing
insertion of synthetic polyadenylation cassettes will be required to test this possibility in
vivo. Additionally, applying recent technological advancements, such as the RNAtargeting Cas13d system will be required to address the role of the Rroid RNA during
group 1 ILC development and maturation163.
Although we did not find a role for the Rroid RNA to regulate the expression of Id2
directly, we did find that abrogation of Rroid-RE1, an ATAC-accessible site specific to
ILC1s, was sufficient to confer a partial phenocopy of the Id2 and maturation defects we
observed in Rroid-/- group 1 ILCs. Long-range chromatin looping interactions between
promoters and enhancers play a critical role in the regulation of gene expression, and
chromatin loops in mammalian genomes are determined by cohesin and CTCF164.
Cohesin promotes the extrusion of chromatin loops until it encounters CTCF bound to
DNA165. While CTCF binds specific DNA sequences, recent evidence indicates that
transcription significantly contributes to positioning cohesin in the mammalian genome166.
In this study, we showed that the Rroid locus and Id2 promoter interact with each other
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through a long-range chromatin loop. Thus, in future studies it will be important to establish
the role of Rroid transcription in the localization of CTCF and cohesin both at this locus,
and in the formation of this long-range interaction with the Id2 locus.
One important factor influencing the epigenetic state of immune cell populations are
extracellular signals derived from the tissue microenvironment. Indeed, the homeostasis and
function of the different ILC subsets is controlled by tissue- and environmentally-derived
cues135. For example, NK cells and ILC1s uniquely require IL-15 for development, function,
and homeostasis. Indeed, while we performed the studies described here, IL-15 was
suggested by another group to promote NK cells in part through regulating Id2
expression55. In this study, we found that STAT5 binds to specific elements within the
Rroid locus in response to IL-15 stimulation in NK cells and that this locus is necessary
for adequate STAT5 deposition at the Id2 promoter in ILC1s, which in turn is critical to
induce Id2 expression. Thus, our results provide key mechanistic insight into how IL-15
regulates ILC1 functions and lineage identity. Importantly, whether STAT5 promotes the
generation of long-range chromatin interactions between the Rroid locus and the Id2
promoter is still unclear. Future studies, including interrogation of long-range chromatin
interactions in the presence or absence of IL-15 stimulation, will be required to understand
the how Rroid and STAT5 converge to promote Id2 in group 1 ILCs.
In summary, our results provide evidence that a cis-regulatory element
demarcated by lncRNA expression is critical for the function, homeostasis and lineage
identity of a group 1 ILCs. Moreover, this work indicates that epigenetic elements unique
to each ILC subset represent a crucial regulatory layer that determines ILC lineage identity
and functional specification.
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4.5 Figures

Figure 18: The Rroid locus regulates epigenetic marks at the Id2 locus
(A) Histone modifications at the Id2 locus. Gene browser depiction of Id2 locus and
ChIP-qPCR primer locations (above). ChIP-qPCR showing H3K27ac enrichment
within the Id2 promoter and gene body (below). NK cells were expanded in vivo with
IL-2/aIL-2 complexes and sorted from spleen (n=3 groups of 2 pooled mice per
group). Results were normalized to enrichment at the Gapdh locus. Data are
representative of two independent experiments.
(B) H3K36me3 modifications at the Id2 locus. Results reported as in (A).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 19: Reduced chromatin accessibility at the Id2 promoter in the absence of
Rroid
(A) Representative gene browser tracks of ATAC-seq reads at the Id2 locus in Rroid+/+
and Rroid-/- NK cells.
(B) Density plot of log2 fold change distribution for ATAC-seq peaks in Rroid+/+ and Rroid/-

NK cells. Fold changes were estimated as the ratio of the trimmed mean of M-

values (TMM)-normalized read counts in consensus peak regions via the DiffBind R
package. Vertical dashed lines show the 5th and 95th percentiles. The green
arrowhead shows the Id2 promoter.
(C) Relative chromatin accessibility at the Id2 locus in Rroid+/+ and Rroid-/- NK cells.
Chromatin accessibility is depicted as an average of TMM-normalized read counts
across replicates. Statistics were obtained using the DiffBind R package (n=3).
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(D) RNA-seq normalized read counts of genes 1MB up- or downstream of Id2 on
chromosome 12. (n=3).
(E) TMM-normalized ATAC-seq read counts at genes 1MB up- or downstream of Id2 on
chromosome 12. (n=3).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 20: IL-15 dependent induction of Id2 in NK cells requires the Rroid locus
(A) Experimental schematic. NK cells were pooled and sorted as CD3,CD5,CD19NK1.1+ NKp46+ cells and expanded in vitro for 6-7 days using 1000U/mL hIL-2 and
10ng/mL IL-15/IL-15Ra. On the day of the experiment, cells were washed three
times in PBS, and plated in growth medium without cytokines. The cells were
allowed to rest for 5h, then supplemented with IL-15/IL-15Ra and cultured for 3h.
(B) Id2 (left) and Rroid (right) expression in in vitro expanded NK cells stimulated with IL15. Gene expression was analyzed by qPCR. Results are normalized to Hprt (n=3).
(C) qPCR analysis of Id2 expression in Rroid+/+and Rroid-/- NK cells. Sorted splenic NK
cells were expanded as in (A), rested 4h, and stimulated 3h with IL-15/IL-15Ra
complex (n=3).
*p£0.05, **p£0.01, ***p£0.001. One-way ANOVA with Tukey’s post hoc test. All error bars
represent SEM.
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Figure 21: STAT5 accumulation at the Id2 promoter in NK cells depends on the Rroid
locus
(A) Representative flow cytometry plots of splenic NK cell maturation in Stat5a+/+
Stat5b+/+ and Stat5a-/- Stat5b+/- mice. Data are representative of two independent
experiments.
(B) Fold change of Id2 expression in splenic control (Stat5a+/+ Stat5b+/+) or Stat5a-/Stat5b+/- NK cells (n=4 Stat5a+/+ Stat5b+/+ and 5 Stat5a-/- Stat5b+/- mice pooled from
two independent experiments). Normalized to Hprt expression and shown as fold
change relative to controls.
(C) STAT5 occupancy at the Id2 promoter. Splenic NK cells were sorted and expanded
in vitro for 7d. Cells were rested for 2h in unsupplemented media, then stimulated
with 20ng/mL IL-15/IL-15Ra complex for 1h. Fixed nuclei were then isolated for
chromatin immunoprecipitation and qPCR (n=3 biological replicates per group).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 22: T-bet does not regulate Id2 expression in NK cells
(A) Representative flow cytometry plots (left) and enumeration (right) of splenic NK cells
in Tbx21+/+ and Tbx21-/- mice. (n=3-4).
(B) Representative flow cytometry plots (left) and frequencies (right) of maturing splenic
NK cells in Tbx21+/+ and Tbx21-/- mice. (n=3-4).
(C) Expression of Tbx21 as measured by qPCR in Tbx21+/+ and Tbx21-/- mice. (n=3-4).
(D) Expression of Id2 as measured by qPCR in Tbx21+/+ and Tbx21-/- mice. (n=3-4).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 23: Depletion of Rroid RNA does not affect Id2 expression
(A) Schematic of locked nucleic acid (LNA) experiment. Sorted wild-type splenic NK cells
were expanded ex vivo for 7d and electroporated with either 4µM control LNA or a
4µM mix of four LNAs targeting the Rroid RNA and cultured for either 6h or 24h.
(B) qPCR analysis of Rroid expression at the indicated time points following
electroporation with LNAs (n=2 biological replicates). Data are representative of two
independent experiments. Normalized to Hprt expression and shown as fold change
relative to controls.
(C) qPCR analysis of Id2 expression at the indicated time points following
electroporation with LNAs, as in (B). (n=2 biological replicates).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 24: Targeting strategy for Rroid-P1 and Rroid-RE1-deficient mice
(A) Gene browser ATAC-seq tracks showing open chromatin within the Rroid locus.
Highlighted are open chromatin peaks and CRISPR/Cas9-targeted regions for the
Rroid-P1 and Rroid-RE1 knockouts.
(B) Closeup genome browser view and CRISPR/Cas9 targeting strategy for Rroid-P1
deletion. This deletion targeted the promoter and first exon of Rroid. Locations of
sgRNAs and genotyping primers are shown.
(C) Closeup genome browser view and CRISPR/Cas9 targeting strategy for Rroid-RE1
deletion. Locations of sgRNAs and genotyping primers are shown.
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Figure 25: The Rroid locus forms a long-range chromatin loop with the Id2 promoter
(A) Chromatin conformation capture (3C) of interactions between the Id2 promoter and
the indicated genomic regions. Data are normalized to interaction frequency of
ligated BAC templates containing the regions of interest. Primer locations are
indicated by arrows; the bait primer located in the Id2 promoter is indicated by the
red arrow. (n=3 biological replicates). Data represent two independent experiments.
(B) Gene browser view of STAT5 ChIP-seq showing binding at the Rroid locus in the
presence or absence of IL-15 stimulation for 2h at 20ng/mL.
(C) ChIP-qPCR of STAT5 occupancy at the Id2 promoter, Rroid-P1, Rroid-RE1, and
Actb in expanded splenic NK cells.
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Figure 26: Deletion of Rroid-RE1 results in decreased mature NK cells and Id2
expression
(A) Absolute numbers of splenic NK cells in 6-8-week-old Rroid-P1-/-, Rroid-RE1-/-, and
Rroid+/+ littermate control mice (n=9 Rroid+/+, 6 Rroid-P1-/-, and 3 Rroid-RE1-/- mice
per group).
(B) Fold change in Rroid expression in splenic NK cells sorted from 6-8-week-old RroidP1-/-, Rroid-RE1-/-, and Rroid+/+ littermate control mice as measured by qPCR (n=7
littermate controls (Rroid+/+), 6 Rroid-P1-/-, and 3 Rroid-RE1-/- mice per group).
Normalized to Hprt expression and shown as fold change relative to littermate
controls.
(C) Fold change in Id2 expression in splenic NK cells sorted from 6-8-week-old Rroid-P1/-

, Rroid-RE1-/-, and Rroid+/+ littermate control mice as measured by qPCR as in (B).
98

(D) Representative flow cytometry plots showing splenic NK cell maturation in in 6-8week-old Rroid-P1-/-, Rroid-RE1-/-, and Rroid+/+ littermate control mice. Gated on live,
CD45.2+ CD3,CD5,CD19- NK1.1+ NKp46+ cells.
(E) Frequency of maturing NK cell subsets. Splenic NK cells from 6-8-week-old RroidP1-/-, Rroid-RE1-/-, and Rroid+/+ littermate control mice were gated on live, CD45.2+
CD3,CD5,CD19- NK1.1+ NKp46+ cells and analyzed for maturation markers.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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CHAPTER 5: Interrogation of putative Id2 regulatory elements in all ILC subsets
5.1 Abstract
In Chapters 2-4, we showed that the Rroid locus specifically regulates group 1 ILC lineage
identity by controlling Id2 expression in these cells. Importantly, expression of Id2 in ILC2s
and ILC3s was unaffected, and in concordance with this the numbers of ILC2s and ILC3s,
as well as their progenitors, were unaffected in Rroid-/- mice. Thus, we hypothesized that
lineage-specific regulatory elements or lncRNAs may promote Id2 expression and
homeostasis in other ILC subsets. To test this hypothesis, we used the CRISPR/Cas9
system to generate additional knockouts of putative Id2 regulatory elements in vivo. In
contrast to the phenotype we observed in Rroid mice, we found that following genetic
deletion of one such region, which we called Id2-DS3, ILC2 homeostasis is significantly
disrupted. We show that a significant reduction in ILC2 populations in the lung and small
intestine is specific to the ILC2 lineage, as NK cells, ILC1s, and ILC3s are not affected.
Moreover, loss of this region specifically affected ILC2s at the ILC2P stage in the bone
marrow but did not impact the generation of CHILPs. Altogether, these data suggest that
Id2 is regulated by specific regulatory elements in different ILC lineages.
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5.2 Introduction
In previous Chapters, we showed that the lncRNA Rroid was specifically
expressed in group 1 ILCs, and that deletion of this locus impaired the maturation and
function of these cells. We showed that the Rroid locus promoted group 1 ILCs by
regulating expression of Id2, a key transcriptional regulator in ILCs that promotes their
lineage identity by suppressing E-protein activity. Importantly, we failed to find a role for
the Rroid locus in ILC2 or ILC3 homeostasis in these studies. Thus, whether alternative
regulatory elements in ILC2s and ILC3s regulate these lineages is unknown.
One of the key benefits of enhancer-based gene regulation is their ability to
activate transcription over long distances. This property allows for multiple enhancers to
regulate the same gene using different combinations of transcription factors and
transcriptional coactivators in a cell type-specific manner. For example, multiple distinct,
cell type-specific enhancers are associated with regulation of the same genes in both
embryonic stem (ES) cells and macrophages, and enhancers with partially-redundant
function control expression of Cd4 in thymocytes following positive selection167,168. Our
previous results showing that a specific lncRNA locus, and a regulatory element within
that locus, promoted Id2 expression in group 1 ILCs indicated that multiple regulatory
elements may combine to control Id2 expression in group 1 ILCs. These results also raised
the possibility that distinct regulatory elements might control Id2 in other ILC subsets.
As discussed previously, a key mechanism by which DNA regulatory elements
such as enhancers, or lncRNA transcription might regulate expression of target genes is
through the formation of long-range chromatin loops dependent on CTCF166,169. Previously
though to act as an insulator, CTCF is now known to play key roles in both negatively and
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positively regulating gene expression by controlling genome architecture. Indeed, recent
studies have shown that CTCF sites interact with active promoters and enhancers, and
positively correlate with gene expression169,170. Moreover, distal CTCF-bound sites can
form long-range interactions with promoters that are not blocked by intervening CTCF
sites, suggesting that complex regulation of CTCF-dependent chromatin looping plays
important roles in gene regulation. However, the potential roles that CTCF-dependent
chromatin interactions play in ILCs is not known.
Here we examine genomic data for additional evidence of lncRNA expression,
CTCF binding sites, and ATAC-accessible regulatory elements for clues to identify key Id2
regulatory elements in ILCs. We identified two candidate regions, which we termed Id2DS2 and Id2-DS3 for further study. We further show that in vivo, Id2-DS2 was dispensable
for ILC homeostasis. However, Id2-DS3 was specifically required for steady state
populations of ILC2s in the lung, gut, and bone marrow. Thus, in addition to group 1 ILCspecific regulation of Id2 by the Rroid locus, we show that Id2 is likely to be regulated in a
lineage-specific manner in ILC2s, further supporting a model wherein this key ILC gene is
controlled by key regulatory elements in a cell type-specific manner.

5.3 Results
5.3.1 Generation of Id2 regulatory element-deficient mice
The Rroid locus is an Id2 cis-regulatory element that promotes expression of Id2
in a cell-intrinsic manner in group 1 ILCs via the formation of long-range chromatin loops.
Furthermore, while all ILCs require Id2, but we failed to find a role for the Rroid locus in
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homeostasis of ILC2s and ILC3s. Therefore, we hypothesized that additional lncRNAs or
regulatory elements near Id2 might regulate its expression in other ILC subsets. In order
to investigate this, we re-examined RNA-seq, ATAC-seq, and predicted CTCF binding
sites from Ensembl’s database (Figure 27 and 79,80).
Since the completion of our original studies, the Ensembl database has been
updated to include additional lncRNAs that have been annotated in the ~300kb interval
downstream of Id2. One of these lncRNAs, Gm36287, was expressed at extremely low
levels in RNA sequencing data (data not shown), and aside from Rroid none of these
lncRNAs was differentially expressed in RNA-seq datasets from mature ILCs (Figure 27).
The Ensembl database also identified several putative CTCF binding sites, some of which
were associated with ATAC-accessible chromatin. Further analysis of ATAC-seq datasets
showed extensive remodeling and increases in chromatin accessibility from the CLP stage
through mature ILCs (Figure 4B and 27). As with the Rroid locus, several of these putative
cis-regulatory elements were specific to one to two lineages of ILCs80. However, unlike
group 1 ILC-specific expression of the Rroid lncRNA, few features clearly suggested a key
regulatory element on which to focus our future studies. Additionally, due to the scarcity
of mature ILCs in mice, our ability to interrogate key long-range chromatin interactions
using sequencing methods such as Hi-C and ChIA-PET was limited. Therefore, to begin
to address our hypothesis in vivo, we decided to use a similar approach to the one we
used to investigate the Rroid locus. We divided the genomic interval downstream of the
Id2 locus into four ~60kb segments containing CTCF binding sites, annotated lncRNAs,
and differentially accessible chromatin. We named these intervals Id2 Downstream
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Sequences 1-4 (Id2-DS1 – Id2-DS4; Figure 27). We then used the CRISPR/Cas9 system
to design sgRNAs and generate mouse lines deficient in these segments.

5.3.2 Id2-DS2-/- mice do not exhibit defects in ILC homeostasis
We hypothesized that separate ILC lineages might be regulated by distinct cisregulatory elements, including lncRNAs or enhancers located in proximity to CTCFdirected chromatin loops. In examining the genomic region downstream of Id2, we
determined that Id2-DS2 contained two annotated lncRNAs, multiple differentially ATACaccessible regulatory elements, and multiple potential CTCF binding sites that may be
involved in chromatin loop formation (Figure 27). Although these lncRNAs were not
expressed in RNA-seq datasets from mature cells, we could not rule out their expression
in ILC precursors. Therefore, to test whether Id2-DS2 might be involved in regulating ILCs,
we generated Id2-DS2-/- mice using the CRISPR/Cas9 system.
Upon examination of splenocytes from Id2-DS2-/- mice and their littermate controls
(Id2-DS2+/+ and Id2-DS2+/-) we did not observe any alterations to either CD4+ or CD8+ T
cells, or myeloid cell subsets (Figure 28A). Likewise, upon stimulation we found no
differences in production of IFN-g in CD4+ or CD8+ T cells isolated from naïve mice (Figure
28B). Interestingly, we also failed to see any differences in the numbers of Id2-DS2-/- NK
cells, and also observed no differences in their maturation in the spleen (Figure 29A-B).
Upon stimulation, Id2-DS2-/- NK cells also produced similar amounts of IFN-g (Figure
29C). Consistent with these results in the spleen, we also failed to find any defects in NK
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cell and ILC1 homeostasis in other tissues such the liver and lung (Figure 30A-C). Thus,
our results suggest that the Id2-DS2 region is not required for group 1 ILC homeostasis.
We next examined whether homeostasis of ILC2s and ILC3s was affected in the
absence of Id2-DS2. In the lung, we observed equivalent numbers of ILC2s at steady state
(Figure 31A). Lung ILC2s also secreted IL-5 and IL-13 and promoted the recruitment of
eosinophils to the lung parenchyma in response to the protease allergen papain,
suggesting their functions also remained intact (Figure 31B-C). In the small intestine, we
found that homeostasis of ILC3 populations was also unchanged (Figure 31D-E).
Altogether, these data suggest that the Id2-DS2 region is dispensable for ILC homeostasis
and underlines the specificity of the Rroid locus for regulating Id2 in group 1 ILCs.

5.3.3 ILC2 homeostasis is disrupted in Id2-DS3-/- mice
In addition to the Id2-DS2-/- mice, we also generated mice deficient Id2-DS3-/- mice.
The Id2-DS3 region did not contain any annotated lncRNAs, nor did it express any
unclassified RNAs in mature ILCs (Figure 27). However, Id2-DS3 did contain multiple
potential CTCF motifs, including CTCF sites located in close proximity to ATAC-accessible
regions. As in the Id2-DS2-/- mice, we observed that Id2-DS3-/- mice had normal numbers
of CD4+ and CD8+ T cells (Figure 32A). Numbers of dendritic cells in the spleen and other
tissues were also normal, including the Id2-dependent CD8a+ DCs171 (Figure 32B-C).
Moreover, Id2-DS3-/- mice had no differences in their total NK cells, or in NK cell maturation
in the spleen (Figure 32D). Consistent with this, we also observed normal numbers of NK
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cells and ILC1s in the liver (Figure 32E). Altogether, this data suggests that Id2-DS3 is
not required for the homeostasis of group 1 ILCs.
We next asked whether ILC2 or ILC3 homeostasis was affected by loss of Id2DS3. We first profiled Id2-DS3-/- lung lymphocytes and observed a dramatic reduction in
ILC2 numbers in this tissue compared to littermate controls (Figure 33A-B). Loss of this
region also resulted in fewer IL-5+ Lin- CD90.2+ ILCs in the lung at steady state (Figure
33C). Id2-DS3 was required for steady state numbers of ILC2s in the small intestine as
well, as we observed a significant reduction in GATA3+ ILC2s from Id2-DS3-/- mice
compared to their littermate controls (Figure 33D-E). This phenotype was specific to
ILC2s, as total ILC3s as well as the ILC3 subpopulations of CD4+ LTi, NKp46- ILC3s, or
NKp46+ ILC3s were affected in the absence of Id2-DS3 (Figure 33F). Altogether, these
results suggest that the Id2-DS3 region is specifically required for ILC2 homeostasis in
mice.

5.3.4 Id2-DS3 is required for the generation of ILC2 progenitors in the bone marrow
Group 2 ILCs develop in the bone marrow from common helper ILC progenitors
(CHILPs) which give rise to ILC2 progenitors (ILC2Ps; Figure 1). To determine whether
ILC2 homeostasis in the bone marrow was also disrupted in Id2-DS3-/- mice, we identified
Lin- CD90.2+ CD127+ ST2+ ILC2s in the bone marrow. While this population comprised
0.116±0.038% of cells in Id2-DS3+/- bone marrow, these cells were almost entirely absent
in Id2-DS3-/- mice (0.014±0.005%; Figure 34A-B). Therefore, we next examined the
precursor populations to these cells. We found that Id2-DS3 was necessary for the
106

formation of ILC2P, as this population was also reduced in Id2-DS3-/- mice (Figure 34CD). This effect was specific to ILC2Ps, as we did not observe any changes in the numbers
of CHILPs in the absence of Id2-DS3 (Figure 34C-D). Altogether, our data indicate that
Id2-DS3 harbors regulatory elements responsible for promoting Id2 expression in an ILC2specific manner.

5.4 Discussion
In this study, we aimed to extend our findings in Rroid-/- mice to uncover novel
regulatory elements for controlling Id2 in separate ILC lineages. To that end, we used the
CRISPR/Cas9 gene editing system to generate mouse lines deficient in regulatory regions
containing lncRNAs, potential Id2 enhancers, or CTCF binding sites to screen for genomic
regions containing key cis-regulatory elements for controlling Id2 expression in ILCs. We
found that one of these regions, Id2-DS2, was not required for the steady state
homeostasis of ILCs, or for NK cell and ILC2 effector functions. In contrast, we showed
that Id2-DS3 critically controlled ILC2 homeostasis. While homeostasis of CD4+ and CD8+
T cells, Id2-dependent dendritic cells, NK cells, ILC1s, ILC3s, and CHILPs were normal in
Id2-DS3-/- mice, we observed a dramatic reduction in ILC2s in the lung and small intestine,
and in ILC2 progenitors in bone marrow. Thus, these data uncover Id2-DS3 as a key
regulatory element for controlling ILC2s.
In this series of experiments, we focused identifying potential key Id2 cis-regulatory
elements by broadening our search to include newly annotated lncRNAs, predicted CTCF
binding sites, and putative regulatory elements marked by ATAC-accessible chromatin.
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Although RNA-seq analysis identified very low expression of one of these lncRNAs,
Gm36287, deletion of the vast majority of its genomic sequence in the Id2-DS2-/- mice did
not result in any appreciable defects to ILC homeostasis. It is important to note that we
cannot rule out any effects to other Id2-dependent processes in these mice. For example,
future studies addressing Th1 polarization or the generation of effector CD8+ T cells will
have to be carried out. Additionally, interrogation of Id2 expression in these cell types will
be required to understand whether Id2-DS2 regulates Id2 expression at a sub-threshold
level. Altogether, these studies will shed light on whether Id2-DS2 regulates Id2
expression and its role in immune cell homeostasis.
In contrast to Id2-DS2, we found that Id2-DS3 did not contain annotated lncRNAs,
nor did we find any evidence of lncRNA transcription in mature ILCs. Instead, we observed
several peaks of ATAC-accessible chromatin in all ILCs, some of which were associated
with predicted CTCF binding sites from Ensembl. Upon deletion of the Id2-DS3 regulatory
region, we observed a dramatic reduction in ILC2 in the lungs, small intestine, and bone
marrow. We then traced this loss of ILC2 homeostasis back to ILC2Ps, which were lost
as well.
These findings suggest a model wherein Id2 is regulated by key regulatory
elements in a cell type-specific manner (Figure 35). This raises several important
questions that will need to be addressed in future studies. First, what is the biological basis
for loss of ILC2s and ILC2Ps in Id2-DS3-/- mice? Future studies interrogating the survival
and proliferative capacity of the few remaining ILC2Ps in these will be required to begin
addressing these questions. A second, related question is whether exogenous
administration of key ILC2 survival cytokines, such as IL-2, IL-7, and IL-33 are sufficient
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to overcome loss of Id2-DS3? Thus, due to the sparse numbers of Id2-DS3-/- ILC2s, in vivo
administration of these cytokines will allow for tracking the homeostasis of ILC2Ps in bone
marrow and tissue ILC2 populations. A simultaneous approach of culturing CHILPs, which
appear unaffected in the absence of Id2-DS3, in ILC2-inducing conditions on OP9 and
OP9-DL1 stromal cells will also help to answer this question. This technique will also
answer a third question: do Id2-DS3-/- ILC progenitors adopt alternative fates, such as B,
T, or myeloid cells in the absence of this locus?
Finally, a key question is of the molecular mechanism, and whether Id2-DS3
regulates ILC2s through Id2. Rescue experiments, wherein Id2 is retrovirally expressed in
Id2-DS3-/- CHILPs and then transferred into irradiated hosts or cultured on OP9 stroma
will be required to determine whether Id2 can rescue this phenotype. Simultaneously
transcriptional profiling of the remaining ILC2s or their precursors will uncover the specific
genes and pathways regulated by Id2-DS3. Lastly, it will be important to determine
whether this phenotype is dependent on CTCF-dependent chromatin looping, or through
some other mechanism, by generating novel CTCF binding site mutant mouse lines, or
through in vitro screening with mice constitutively expressing Cas9. Altogether, the results
presented here suggest that while the Rroid locus specifically regulates group 1 ILCs
through Id2, additional regulatory regions play key roles in controlling Id2, and thus the
homeostasis of ILCs, in a lineage-specific fashion.
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5.5 Figures

Figure 27: Genomic view of Id2-DS1 - Id2-DS4
Genome browser view showing ATAC-seq and RNA-seq tracks from ILCs (top). Below,
gene models of lncRNAs downstream of Id2, as well as predicted CTCF sites from
Ensembl. Also shown are Id2 Downstream Sequences 1-4 (Id2-DS1 – Id2-DS4). Id2-DS2
and Id2-DS3 were targeted by the CRISPR/Cas9 system to generate knockouts and are
shown in red. Note: some lncRNAs exhibit multiple isoforms; only the main isoform is
shown in this figure.
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Figure 28: Id2-DS2 is dispensable for myeloid cells and T cells
(A) Absolute numbers of the indicated cell populations in spleens of Id2-DS2-/- and
littermate controls. (n=4).
(B) IFN-g production by splenic CD4+ T cells (left) or CD8+ T cells (right) isolated from
naïve mice. Splenocytes were stimulated in the presence of media alone PMA and
Ionomycin for 4h in the presence of Brefeldin A. (n=4).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 29: Normal NK cell development in absence of Id2-DS2
(A) Representative flow cytometry plots showing NK cells in the spleens of Id2-DS2-/mice and littermate controls. Representative of two independent experiments.
(B) Representative flow cytometry plots (left) and enumeration (right) of maturing NK
cells in the spleens of Id2-DS2-/- mice and littermate controls. (n=4). Representative
of two independent experiments.
(C) IFN-g production by splenic NK cells. Representative flow cytometry plots (left) and
frequency of IFN-g+ NK cells from splenocytes stimulated for 4h with either media
alone or 20ng/mL IL-12 and 20ng/mL IL-18. (n=4). Representative of two
independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 30: Id2-DS2 is not required for ILC1s in the liver or lung
(A) Representative flow cytometry plots showing gating for liver CD49a+ ILC1s and
CD49b+ NK cells. Pre-gated on CD45+ CD3,CD5- cells.
(B) Absolute number of ILC1s and NK cells in the livers of Id2-DS2-/- mice and their
littermate controls. (n=4).
(C) Absolute numbers of lung ILC1s and NK cells gated as in (A). (n=3-4).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 31: ILC2s and ILC3s are normal in Id2-DS2-/- mice
(A) Absolute numbers of ILC2s in the lungs of Id2-DS2-/- mice and their littermate
controls. Gated on Lin (CD3,CD5,CD11b,CD11c,B220,NK1.1)- CD45+ CD127+ ST2+
cells. (n=4). Data are representative of two independent experiments.
(B) IL-5 (left) and IL-13 (right) in ILC2s isolated from the lungs of mice treated with 10µg
papain on days 0, 1, and 2, then euthanized for analysis on day 5. Lung lymphocytes
were isolated by digestion and incubated with either media alone or PMA and
Ionomycin for 4h in the presence of Brefeldin A. (n=3-4).

114

(C) Eosinophils (CD45+ Ly-6G- CD11c- Siglec-F+) from the lung parenchyma of mice
treated with papain as in (B). (n=3-4).
(D) Frequency of ILC3s in the small intestines of Id2-DS2-/- mice or their littermate
controls. Gated on CD45+ CD3,CD5- CD90.2+ RORgt+ cells. (n=5).
(E) Frequencies of ILC3 subpopulations. Pre-gated as in (D). (n=5).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 32: Id2-DS3 is dispensable for ILC1s and NK cells
(A) Absolute numbers of CD45+ CD3,CD5+ T cell populations in the spleens of Id2-DS3-/mice and their littermate controls. (n=3). Representative of two independent
experiments.
(B) Absolute numbers of CD45+ CD11c+ MHC-II+ dendritic cells in Id2-DS3-/- mice and
their littermate controls. (n=3).
(C) Representative flow cytometry plots of CD8a+ DCs and CD11b+ DCs gated as in (B).
(D) Absolute number of NK cells in the spleens of Id2-DS3-/- mice and their littermate
controls. (n=3). Gated on CD45+ CD3,CD5- NK1.1+ NKp46+ cells. (n=3).
Representative of two independent experiments.
(E) Frequencies of maturing NK cells in Id2-DS3-/- mice and their littermate controls.
Pre-gated as in (D). (n=3). Representative of two independent experiments.
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(F) Absolute numbers of CD49a+ ILC1s and CD49b+ NK cells in the livers of Id2-DS3-/mice or littermate controls. Pre-gated on CD45+ CD3,CD5- cells. (n=3).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 33: Id2-DS3 is required for steady state ILC2 homeostasis
(A) Representative gating of ILC2s in the lungs of Id2-DS3-/- mice and their littermate
controls. Pre-gated on CD45+ cells. Lineage cocktails consist of
CD3,CD5,CD11b,CD11c,B220, and NK1.1.
(B) Absolute numbers of ILC2s in the lungs of Id2-DS3-/- mice and their littermate
controls. Gated as in (A). (n=6). Data pooled from two independent experiments.
(C) IL-5 production in ILCs (Lin- CD90+) isolated from lungs of naïve mice. Lung
lymphocytes were isolated by digestion and incubated with either media alone or
PMA and Ionomycin for 4h in the presence of Brefeldin A. (n=3).
(D) Representative flow cytometry gating of ILC2s and ILC3s from the small intestines of
Id2-DS3-/- mice and their littermate controls. Cells were pre-gated on CD45+
CD3,CD5- CD90.2+ cells. ILC2s were then gated as GATA-3+. RORgt+ ILC3s were
subdivided based on expression of NKp46 and CD4.
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(E) Frequency of ILC2s in the small intestines of Id2-DS3-/- mice and controls. (n=6).
Data pooled from two independent experiments.
(F) Frequencies of ILC3s (left) or ILC3 subpopulations (right) in the small intestine.
(n=3). Representative of two independent experiments.
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 34: Id2-DS3 regulates ILC2 levels by promoting ILC2Ps
(A) Representative flow cytometry plots showing gating of ILC2s in the bone marrow.
Lineage markers consisted of CD3,CD5,CD11b,CD11c,CD19,FceRI, Ter119, Ly6G,
and NK1.1.
(B) Frequency of ILC2s in the bone marrow of Id2-DS3-/- mice and controls. (n=6). Data
pooled from two independent experiments.
(C) Representative flow cytometry plots showing gating of CHILPs and ILC2Ps in the
bone marrow. Pre-gated on lineage markers consisted of CD3,CD5,Gr-1, NK1.1, and
Ter119. CHILPs were identified as Lin- Flt3- CD127+ a4b7+ CD25-. ILC2Ps were LinFlt3- CD127+ a4b7+ CD25+.
(D) Frequencies of CHILPs and ILC2Ps in Id2-DS3-/- mice and controls. (n=3).
*p£0.05, **p£0.01, ***p£0.001. Two-tailed t-test. All error bars represent SEM.
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Figure 35: Model of Id2 regulation in ILCs
A model of Id2 regulation in ILC2s and group 1 ILCs. Above, cartoon representation of the
Id2, Id2-DS3, and Rroid loci. Indicated are a subset of CTCF binding sites and putative
enhancers. Model is not drawn to scale. Below, left: potential model of Id2 regulation in
ILC2s. In this model, Id2-DS3 may form CTCF-dependent long-range interactions with the
Id2 locus. Below, right: potential model of Id2 regulation in group 1 ILCs. Rroid forms a
chromatin loop with Id2, which controls STAT5 deposition downstream of IL-15. Whether
this process depends on CTCF, and whether additional transcription factors are involved,
is unknown.
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CHAPTER 6: Discussion and future directions
6.1 Summary of findings
In this study we hypothesized that lncRNAs might play directly regulate gene expression
or mark key regulatory elements for controlling ILC homeostasis or function. In Chapter
2, we showed that ILCs express lncRNAs in a lineage-specific manner. Specifically, a cisregulatory element demarcated by the transcription of the lncRNA Rroid regulated group
1 ILC steady state numbers and effector functions, but not those of ILC2s or ILC3s. In
Chapter 3, we showed that the Rroid locus was required for steady state NK cell and ILC1
populations by promoting the maturation of these cells. This was due to loss of lineage
identity in these cells, as Rroid-/- NK cells exhibited significantly increased levels of key
genes marking adaptive lymphocytes. This phenotype was dependent on Id2, because
expression of this key ILC lineage-defining factor was significantly decreased in Rroid-/mice and could be rescued upon ectopic Id2 expression. In Chapter 4 we showed that in
response to the cytokine IL-15, the Rroid locus regulated the functions and lineage identity
of ILC1s by promoting chromatin accessibility and STAT5 deposition at the promoter of
Id2. In Chapter 5 we generated additional mouse lines genetically deficient in non-coding
elements to determine whether these elements regulated Id2 in other ILC lineages. We
demonstrated that the Id2-DS3 cis-regulatory elements are required for ILC2 homeostasis
by promoting the formation of ILC2Ps in the bone marrow. Thus, this study provides
evidence that non-coding elements unique to each ILC subset, some of which are
responsive to extracellular cues, are critical to control the identity and function of ILCs.
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6.2 Key findings of this work
6.2.1 lncRNAs are expressed in ILCs in a cell type-specific fashion
In Chapter 2 we examined expression of lncRNAs in high throughput sequencing
datasets from mature ILC populations sorted from intestinal tissues79,80. Advances in
sequencing technologies over the past several years have allowed for identification of a
large amount of non-protein coding transcription in eukaryotic cells. Projects such as
GENCODE and NONCODE have extensively documented the landscape of non-coding
transcription in a number of cell types89,172. In the years since these initial discoveries,
lncRNAs have been shown to play diverse roles in the regulation of both development of
immune cells and inflammatory responses87,99,101,115,117,119,120,173. One of the key findings of
the majority of these studies was that lncRNAs are often highly induced by sensing of
environmental signals by immune cells, such as cytokines or Toll-like receptor ligands.
Thus, a variety of environmental signals can regulate the development and function of
immune cells through lncRNAs.
Like other innate immune cells, ILCs are critically dependent on environmental
cues, such as cytokine-derived signals, for their development and maintenance7,11,42.
Additionally, sensing of a diverse range of additional environmental cues such as
neurotransmitters and neuropeptides, or indicators of nutrient state like retinoic acid and
AHR ligands are also key signals controlling ILC homeostasis and effector
responses26,69,71,174-179. Thus, this raises the question of whether lncRNAs might play an
important role in the homeostasis of ILCs.
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Thus, we sought to address this question in this thesis. Unsurprisingly, upon
examination of transcriptomic data from ILCs, we found a large number of lncRNAs
expressed in at least one lineage (data not shown). However, lncRNAs have been
described to work through a variety of mechanisms, including through cis- and trans
interactions with chromatin, or via protein-RNA complexes in the nucleus and cytosol130.
Moreover, consistent with other studies, many lncRNAs were expressed at very low levels,
making them challenging to study89. Therefore, to overcome these obstacles, we focused
our studies on lncRNAs with three main criteria: those that were highly expressed, those
that were specifically expressed in a single ILC lineage, and those that were located near
key ILC-specific genes. In narrowing our search, we found a total of 83 lncRNAs that were
specifically expressed in a single subset of ILCs, including Rroid. Thus, we think this
strategy will be useful in future studies to delineate key regulatory elements for controlling
immune cells, including ILCs.
It is important to note that the criteria for identifying key ILC-specific lncRNAs likely
excludes lncRNAs with important functions in ILCs. As we noted above, many lncRNAs
are highly expressed in multiple subsets of ILCs and may be critically important for their
homeostasis and functions of these cells. Moreover, we predict that lncRNA expression is
dynamically regulated in ILCs by both developmental stage and activation state. In our
study, Rroid was significantly induced by activation of NK cells with IL-15 and was critical
for NK cell cytokine and degranulation responses downstream of Id2. Therefore, it is likely
that lncRNAs represent a key regulatory layer to control ILC effector responses
downstream of activation by cytokines or other environmental signals. Further dissection
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of these pathways using transcriptomic analysis and functional screening of these lncRNA
loci to determine the roles of lncRNA loci in the regulation of ILC homeostasis and function.

6.2.2 Expression of the Rroid lncRNA marks a key regulatory element for the control
of group 1 ILC homeostasis
In Chapter 2, we focused on identifying lncRNAs expressed in ILCs and then
testing those lncRNAs for key functions. Many early studies into the biology of lncRNAs
focused on screening for RNAs that directly modulate expression or activity of their targets
by RNA-protein, RNA-DNA, and RNA-RNA interactions. However, it is becoming
increasingly apparent that transcription and splicing events are critical components for the
function of some lncRNA loci107,108. Moreover, some lncRNAs have been found to encode
for micropeptides180-182. Still other lncRNAs which have been previously described to have
RNA-dependent mechanisms have been re-examined to find that these loci additionally
mark key regulatory elements, even in the absence of transcription of the lncRNA107,114,183.
Therefore, focusing solely on RNA-dependent processes may miss important phenotypes
and mechanisms of gene regulation. Thus, in order to counter these limitations, upon
identifying the Rroid as a group 1 ILC-specific lncRNA transcript, we chose to utilize a
stepwise approach to dissecting this lncRNA locus (Figure 36), first by deleting the Rroid
locus in its entirety to delineate its biological function130.
Using the approach, we showed in Chapter 2 that upon deletion of the Rroid locus,
group 1 ILC homeostasis was significantly impacted, with loss of NK and ILC1s in the
spleen, liver, lung, and intestinal epithelium. We also found that the Rroid locus controlled
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the function of NK cells in these tissues, as cytokine production and degranulation
downstream of cytokine-induced activation or crosslinking of activating receptors was
significantly reduced. Continuing our stepwise approach to dissecting this locus, we
determined that the Rroid locus regulated Id2, but the RNA itself was not directly required
to promote expression of Id2. Instead, Id2 was regulated in part by group 1 ILC-specific
regulatory elements. These data suggest that lncRNAs mark key regulatory elements in
ILCs, and that lncRNAs may play broad roles in regulating ILCs. Indeed, during the course
of our studies, another group published a study describing a role for lncKdm2b in
regulating ILC3 homeostasis87. Altogether, our data establishes that non-coding elements
marked by lncRNA expression are key regulators of ILC homeostasis and function.

6.2.3 The Rroid locus controls mature ILC homeostasis by promoting Id2 and
limiting E-protein activity in mature cells
In Chapter 3, we examined the mechanisms by which the Rroid locus controls
group 1 ILCs and Id2 expression in these cells. As described in Chapter 1, Id proteins are
comprised of four helix-loop-helix (HLH) proteins that lack DNA binding domains, called
Id1-Id4. The classical function of these proteins is thought to be antagonism of E-proteins,
a family of basic-HLH (bHLH) proteins that do contain basic DNA binding domains and
dimerize to act as transcription factors to promote the expression of adaptive lymphocyte
genes151,184. Thus, the Id proteins have been shown to heterodimerize with E-proteins and
act as dominant negative regulators of E-protein activity151,185. Interestingly, in our analysis
of published RNA-seq data in mature ILCs, we found that that these cells express
detectable levels of E-proteins (data not shown), suggesting that the high levels of Id2
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expression in ILCs are required to counterbalance or titrate the activity of E-proteins in
these cells. However, the functional relevance of E-protein expression in mature ILCs is
not known. At the same time, when we started the studies described here, very little was
known about the pathways regulated by the E-Id2 axis in mature ILCs.
In Chapter 2 of this work, we showed that the Rroid locus was required for
appropriate expression of Il12rb2, a key component of the IL-12 receptor that leads to
activation and cytokine production in group 1 ILCs. Moreover, we found significantly
decreased expression of effector molecules in NK cells in addition, including Granzyme B
and Perforin. Overall, this suggests that one function of Id2 in ILCs is to promote full
acquisition of effector programs in NK cells. Indeed, one previous study found that Id2fl/fl
ILC3s which had been inducibly depleted of Id2 by Rorc-cre had significant reductions in
IL-22 production, suggesting that Id2 may promote the acquisition of effector functions in
all ILC lineages.
While Id proteins are transcriptional repressors that have classically been thought
prevent binding of E-proteins to their target genes, it was previously unclear whether
repression of E-proteins was the major mechanism through which Id2 controlled ILC
homeostasis. Moreover, which genes and pathways were regulated by Id2 in mature ILCs
was unexplored. In Chapter 3 of this work, we performed transcription factor footprinting
analysis in our ATAC-seq data from Rroid-/- mice and their controls. This analysis revealed
a significant enrichment for motifs belonging to E-proteins in ATAC-accessible chromatin
in Rroid-/- NK cells. While we cannot rule out the potential for this phenotype to arise
downstream of other Id2-dependent genes, we believe this data supports a model wherein
Id2 represses E-proteins in mature NK cells, and its absence leads to increased activity
127

of E-proteins and de-repression of adaptive lymphocyte genes, such as Cd3d, CD3g, and
Tcf7. Indeed, since the publication of our study, Zook, et al.48 also reported that deletion
of Id2 in NK cells results in de-repression of T-lineage genes and prevents the acquisition
of effector functions.
Importantly, we also found that Rroid, and thus Id2, controlled NK cell proliferation
and survival during maturation. This did not appear to be due to loss of responsiveness to
the key group 1 ILC cytokine IL-15, since we did not observe changes in CD122
expression, or changes in responsiveness to IL-15 in NK cells. Intriguingly, STAT5
signaling was recently shown to promote expression of the anti-apoptotic protein Bcl-2
expression in NK cells186. However, we saw no differences in Bcl2 RNA by qPCR, nor any
loss of another anti-apoptotic gene critical for NK cells, Mcl1187 (data not shown). Thus,
further studies are required to uncover the mechanisms behind how the Rroid locus
controls group 1 ILC survival through Id2. Altogether, this study establishes a central role
for the Rroid locus in controlling Id2-mediated repression of E-protein activity.

6.2.4 The lncRNA locus Rroid forms long-range chromatin interactions to promote
chromatin accessibility and STAT5 deposition at the Id2 promoter
In Chapter 3, we showed that the Rroid locus regulated ILCs by promoting
expression of the key ILC transcriptional regulator Id2. Thus, in Chapter 4 we assessed
the mechanisms by which the Rroid locus regulated group 1 ILCs. As we described in
Chapter 1, lncRNAs are known to work through a variety of mechanisms. Specifically,
functional lncRNAs have been shown to form complexes with protein partners in the
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nucleus and cytosol to modulate the function of transcription factors or chromatin
modifying

complexes99,101,130.

Additionally,

emerging

data

has

suggested

that

transcriptional activity or splicing of lncRNAs may play key roles in promoting target gene
expression107.
Although we were able to test the function of the Rroid lncRNA in vitro using RNAi
(Figures 23 and 36), we were unable to find a role for this lncRNA in directly regulating
Id2, as expression of this gene remained unchanged when Rroid levels were decreased
by locked nucleic acids. Instead, we found that a DNA regulatory element, Rroid-RE1,
found within the Rroid locus was partially responsible for controlling Id2 in group 1 ILCs.
The Rroid locus formed long-range chromatin loops to interact with the promoter of Id2
and promote chromatin accessibility, although the mechanisms behind this remain
unclear. Additionally, the role of STAT5 in the formation of chromatin looping and
activation of Id2 transcription are also unclear. STAT5 itself was recruited to the Rroid
locus in response to IL-15, but whether it interacts with additional transcription factors or
transcriptional co-activators in the context of regulating Id2 transcription is unclear. Indeed,
STAT5 has been shown to interact with, or induce the recruitment of, epigenetic modifying
factors such as Ezh2, LSD1, and HDAC3188-190. However, whether these interactions are
required for the opening of chromatin at the Id2 locus in group 1 ILCs is unknown. Thus,
future studies will need to focus in on delineating the key roles STAT5 plays in regulating
transcription of Id2.
It also remains a possibility that transcription of the Rroid locus, or the RNA
molecule itself, play a role in promoting chromatin accessibility and Id2 transcription.
Indeed, promoters of actively transcribed genes have been shown to have dual functions
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as enhancers110, and transcription of some lncRNAs is also now known to be required to
promote target gene expression107,108. In this study, we were unable to test this possibility
in our experimental systems. Altogether, our data here describes a central role for the
Rroid locus in mediating chromatin accessibility and transcription of Id2. Further studies
addressing the role of STAT5 in this process and that of Rroid transcription using
CRISPR/Cas9-mediated insertion of synthetic polyadenylation cassettes in vivo will be
required to better understand how the Rroid locus accomplishes this task.

6.2.5 Id2 expression in ILCs is controlled by cis-regulatory elements in a lineagespecific manner
In Chapter 3 of this thesis, we showed that the Rroid locus regulated group 1 ILCs
by controlling expression of Id2. Moreover, we showed that in both ILC2s and ILC3s,
expression of Id2 was induced independently of the Rroid locus. Moreover, as our data in
Chapter 2 showed, the Rroid locus did not regulate ILC2 or ILC3 homeostasis or
responses in any of the tissues or models we investigated. Moreover, when we moved
forward in our studies by deleting Id2-DS2 and Id2-DS3, we found that Id2-DS3 specifically
controlled ILC2 homeostasis. Importantly, we have not yet shown that Id2 is specifically
lost in Id2-DS3-/- mice. Additional studies combining cell sorting and qPCR or
transcriptomic analysis will be required to determine whether Id2-DS3 controls Id2
expression in these cells.
Nonetheless, our data suggests that Rroid specifically regulates Id2 expression in
group 1 ILCs, and Id2-DS3 may be responsible for promoting Id2 in ILC2s. Altogether, our
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data suggests that separate ILC lineages utilize distinct regulatory elements to promote
Id2 expression and control their homeostasis. It is not totally surprising that this might be
the case, as multiple enhancers can control the same genes in a lineage-specific or
temporal manner167. However, it does raise the question of whether specific combinations
of transcription factors and transcriptional coactivators are required to either initiate Id2
expression in early ILC precursors in the bone marrow, or to maintain Id2 expression in a
lineage-specific manner in maturing ILCs. Moreover, identifying highly conserved, key
regulatory elements regulating ILCs in a lineage-specific manner may provide insight into
the evolutionary origins of these cells.

6.2.6 Loss of ILC2s in Id2-DS3-/- mice may provide insights into ILC fate decisions
early in development
Acquisition of Id2 expression is one of the key early events regulating ILC
development. Indeed, Id2 is highly expressed in EILPs, the earliest known precursors of
all ILC lineages, as well as in CHILPs and PLZF+ ILCPs7,34,46. In Id2-/- mice, EILPs are
significantly reduced, and CHILPs and mature ILCs are absent, demonstrating the critical
roles these proteins play in controlling ILC homeostasis and development. However, the
specific pathways by which Id2 controls ILCs, and whether Id2 plays important roles in
developmental fate decisions and lineage maintenance of ILCs have remained unclear. In
Chapter 5, we delete a key regulatory element near the Id2 locus, which controls ILC2
homeostasis through the formation of ILC2Ps. For their part, E-proteins such as E2A, E22, and HEB, are critical for the development of adaptive lymphocytes. For example, mice
in which any of these three proteins has been deleted have a deficiency in B cells that
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occurs at the pro-B cell stage191. Likewise, E-proteins are required for normal development
of lymphoid precursors and of T cell development in the thymus155,192,193. Indeed, Notch1
is a target of E2A during thymocyte development, and both proteins cooperate to promote
expression of additional target genes, such as Hes1193.
Overall, these studies lead to a model of ILC development wherein the
hematopoietic progenitors of B and T cells, such as CLPs or lymphoid-primed multipotent
progenitors (LMPPs), express high levels of E-proteins, which are then counteracted by
expression of Id2 in ILC precursors. In support of this model, a recent study by Miyazaki
et al.155 showed that E2A and HEB suppressed ILC fate, as inducible deletion of these
genes in an Il7rcre background resulted in a significant expansion of ILC2s in the thymus
and lymphoid organs of cre-expressing mice. At the same time, ectopic expression of Id2
in hematopoietic progenitors in these mice favored the ILC fate at the expense to
thymocyte development. Interestingly, EILPs were reported to be partially independent of
Id2, as the number of EILPs in Id2-/- were reduced, but not ablated entirely34. However,
work done in NK cells has shown that other members of the Id, such as Id3, can
compensate to some degree in the absence of Id247,48. Indeed, both Id1 and Id3 were
found to be induced in Id2-/- EILPs compared to controls34, suggesting these Id family
members can compensate for the loss of Id2 early in ILC development.
While induction of Id2 expression in ILC precursors is a critical step in ILC
development, the upstream signals regulating its expression are still unclear. In Chapter
4 we showed that in mature NK cells, the Rroid locus promoted open chromatin and
STAT5 deposition at the Id2 promoter in response to IL-15 (Figures 20 and 21). Because
multiple signaling pathways, including those of the IL-2, IL-7, and IL-15 receptors, signal
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through STAT5, it is tempting to speculate that STAT5-dependent signals downstream of
IL-7R might regulate the generation of ILC progenitors through STAT5 and Id2. However,
recent work has shown that although they required Id2, the development of ILCPs and
EILPs are not reduced in the absence of Il2rg or Il7r35. Therefore, while Id2 was not
specifically examined in the context of Il7r-deficient ILCPs, it is likely that additional
transcription factors are responsible for initiating its Id2 expression in these cells.
Moreover, while we have not formally demonstrated that Id2 expression is lost in ILC2P
isolated from Id2-DS3-/- mice, our data suggest that expression of Id2 is initiated in EILPs,
and then maintained in CHILPs, ILC2Ps, and mature ILCs by specific enhancers or
lncRNAs.

6.2.7 Id2-DS3-/- mice may be a tool to dissect the contributions of ILC2s to immunity
in vivo
ILCs and T cells share a requirement for many of the same transcription factors
and have significant overlap in expression cell surface markers. Because of this, it is
difficult to generate ILC-deficient mice using either genetic or antibody-mediated depletion
models. Thus, most studies examining the roles for ILCs in in vivo settings have been
forced to use mouse models requiring bone marrow transfers, or Rag-deficient mice in
which T and B cells are ablated, to study immune responses in the presence or absence
of ILC subsets. This has complicated interpretation of the roles of ILCs in vivo, and the
extent to which the functions of ILCs overlap with those of CD4+ T cells194-196. Thus, there
is a need for mouse models to study ILC deficiency in lymphocyte-replete settings, without
the use of complex genetic tools or depletion strategies196. Our data in Id2-DS3-/- mice
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suggest that while ILC2s are lost, overall T cell numbers remain consistent. While further
studies will need to be carried out to ensure T cell responses proceed normally, we think
our data suggests that Id2-DS3-/- mice for isolating the specific roles of ILC2s in immune
responses. Altogether, our data suggests that mice deficient in Id2 cis-regulatory elements
may be useful tools to study the biological functions of ILCs in vivo.

6.3 Concluding remarks
ILCs have rapidly emerged as key innate mediators of tissue homeostasis and
immune responses in a variety of settings in both human and mouse systems. Because
they lack rearranged antigen receptors, ILCs are also fully reliant on sensing their local
environment for clues on how to respond to perturbations in homeostasis, such as
infection, inflammation, or some other insult. However, despite their importance in the
immune system, exceptionally little is known about how ILCs integrate these
environmental signals into transcriptional and epigenetic programs, and how those
programs ultimately control ILC homeostasis and effector responses. Altogether, the data
presented in this thesis reveal one such mechanism, where induction of an epigenetic cisregulatory element, Rroid, is required for maintaining the lineage identity, maturation, and
functions of group 1 ILCs.
While the delineation of the key transcription factors and progenitor-progeny
relationships of ILCs has proceeded at a rapid pace since their recent discovery, our
understanding of how these cells are regulated at an epigenetic level has lagged far
behind. One key reason for this is due to cell numbers – the low numbers of ILCs that can
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be sorted from tissues (<100,000 cells/tissue/mouse) make techniques for mapping
epigenetic marks, such as ChIP-seq, difficult to accomplish, while totally precluding
attempts to map long-range chromatin interactions that require up to 108 cells197. Although
profiling of accessible chromatin by ATAC-seq provides valuable information, it is also
limited in that it can only detect chromatin accessibility at a particular locus, which does
not imply functionality. Therefore, there is a critical need for the development of new
technologies to assay transcription factor binding and long-range chromatin interaction
with very low input. Indeed, the development of these techniques coupled with recent
advancements in single cell sequencing technologies such as scRNA-seq or scATAC-seq
can also provide valuable information in these small cell populations80,198.
Importantly, although we now know that a large number of lncRNAs are expressed
in ILCs, and that ILCs display very distinct epigenetic profiles, we lack a system to rapidly
screen these cis-regulatory elements for their functionality. Therefore, development of
CRISPR/Cas screening systems, such as with Cas9 or the recently-discovered RNAtargeting Cas13d nuclease163 will be an important step in discovering how lncRNAs and
enhancers regulate ILCs. Moreover, understanding how these cis-regulatory elements
control ILCs, and whether environmental signals are involved in modulating these
regulatory elements, will allow us to target these pathways or develop therapeutic
strategies that may be relevant to human health.
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6.4 Figures

Figure 36: Testing lncRNA function in vivo
In vivo functional testing of lncRNAs remains challenging but is critical to understanding
their relevance in the immune system.
(A) Cell-type specific lncRNA expression profiles can be generated from RNA-seq on
purified cell populations or publicly available datasets.
(B) The functional relevance of these loci encoding these lncRNAs can be quickly and
easily assessed by generating genomic deletions using the CRISPR/Cas9 system.
(C) RNA dependence of functional lncRNA loci can be assessed using shRNAs and
ASOs.
(D) Transcriptional dependence can be determined by insertion of a premature poly-A
cassette using CRISPR/Cas9.
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CHAPTER 7: Materials and Methods
7.1 Experimental model and subject details
7.1.1 Mice
C57BL/6

(Rroid+/+),

B6.SJL-Ptprca

Pepcb/Boy

(CD45.1+),

and

B6(SJL)-

Zbtb16tm1.1(EGFP/cre)Aben (PLZFGFPcre) mice were purchased from The Jackson Laboratory.
Generation of STAT5-deficient mice (Stat5a-/- Stat5b+/-) was described previously199. The
Tbx21-/- mice were from Christopher Hunter. The Rroid-/-, Rroid-P1-/-, Rroid-RE1-/-, Id2DS2-/-, and Id2-DS3-/- mice were generated using the CRISPR/Cas9 system as
described200. Briefly, we designed sgRNAs flanking the loci of interest and used these
sgRNAs and Cas9 to generate double-stranded DNA breaks in C57BL/6 single cell
embryos, which were resolved by non-homologous end joining, ablating the intervening
sequence. The sgRNA sequences can be found in Section 7.6. Genomic deletion of the
Rroid locus was confirmed by PCR. One Rroid+/- line was established and backcrossed
onto the C57BL/6 background for at least 5 generations to control for potential off-target
effects, then intercrossed to generate Rroid-/- mice. For Rroid-P1, Rroid-RE1, Id2-DS2,
and Id2-DS3-deficient mice, genomic deletions in founder mice were confirmed by PCR
and bred by crossing heterozygotes with either heterozygous or homozygous mates; in
these experiments, littermate controls were used. All mice were bred and maintained
under pathogen-free conditions at an American Association for the Accreditation of
Laboratory Animal Care accredited animal facility at the University of Pennsylvania or
National Institutes of Health. Mice were housed in accordance with the procedures
outlined in the Guide for the Care and Use of Laboratory Animals under an animal study
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proposal approved by an institutional Animal Care and Use Committee. Male and female
mice between 6 and 12 weeks of age were used in this study.

7.1.2 Bacteria
Single Listeria monocytogenes 1043S colonies were picked from Brain Heart Infusion
(BHI) agar and cultured in BHI broth shaking at 250rpm at 37°C. Single Salmonella
enterica serovar Typhimurium (strain SL1344) colonies were picked from LB plates and
grown in LB broth shaking at 250rpm at 37°C.

7.2 Method details
7.2.1 Cell isolation
Single cell suspensions from mouse spleen and mesenteric lymph node were
isolated by physical dissociation and filtered through a 70µm cell strainer. For bone
marrow cell isolation, femurs were collected and flushed with 5mL of cold PBS, then
filtered with a cell strainer. For sorts, bone marrow was collected from femurs and tibias
by crushing using a mortar and pestle.
For lungs, mice were perfused with 10mL of PBS through the right ventricle of the
heart prior to isolation. The lungs were then isolated, minced with scissors, and digested
in RPMI + 1mg/mL Collagenase D + 0.2mg/mL DNase I for 45 minutes at 37°C with
shaking at 200rpm. The digested lungs were then passed through a 70µm cell strainer.
The cells were pelleted and purified by bringing up in 40% isotonic Percoll, underlaying
138

80% isotonic Percoll, and spinning at 800xg for 20min at 4°C with low brake.
Hematopoietic cells were collected from the interface.
For isolation of murine liver leukocytes, the liver was perfused with 10ml PBS and
then transferred to DMEM on ice. The liver was then removed from media and minced into
small pieces prior to digestion with DMEM+ 0.5mg/mL Collagenase 4 + 0.2mg/mL DNase
I for 45min at 37°C with shaking at 200rpm. The digested livers were then passed through
a 100µm cell strainer; the remaining pieces were mashed through the same strainer. To
pellet hepatocytes, the digested livers were centrifuged at 20xg for 5min at 4°C. The
leukocyte-containing supernatant was then transferred to a new tube and centrifuged at
450xg for 5min at 37°C. The collected leukocytes were purified over a Percoll gradient as
described for lung leukocyte isolation.
For isolation of small intestine lamina propria lymphocytes, the small intestine was
obtained, opened lengthwise, and the feces shaken out by agitation in ice cold PBS.
Mucus and epithelial cells were removed by first incubating 2x15min at 180rpm and 37°C
in HBSS (Corning) + 2%FBS (Sigma)+ 20mM HEPES (ThermoFisher Scientific)+ 5mM
DTT (Sigma), then 2x15min at 180rpm and 37°C in HBSS+ 2%FBS+ 20mM HEPES+
5mM EDTA, pH8.0. Intestines were thoroughly washed 2x with ice cold PBS and minced
into small pieces with scissors. The minced small intestines were then digested in 20mL
RPMI (Corning)+ 20mM HEPES+ 1X Penicillin/Streptomycin (ThermoFisher Scientific)+
0.05mg/mL Liberase TM+ 0.2mg/mL DNase I. The digested intestines were filtered
through a 100µm cell strainer and purified over a Percoll gradient.
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For isolation of intestinal epithelial lymphocytes, the small intestine was obtained
and opened lengthwise as above. Mucus was removed by incubating 2x15min at 180rpm
and 37°C in HBSS+ 2%FBS+ 20mM HEPES+ 5mM DTT. The intestines were then
incubated 2x15min at 180rpm and 37°C in HBSS+ 2%FBS+ 20mM HEPES+ 5mM EDTA,
pH8.0. The washes were filtered through a 70µm cell strainer, pelleted, and lymphocytes
were purified over a Percoll gradient as above.
For isolation of salivary gland lymphocytes, salivary glands were obtained and
minced in digest medium containing RPMI + 20mM HEPES + 1mg/mL Collagenase D +
0.2mg/mL DNase I for 45 minutes at 37°C with shaking at 180rpm. The digested salivary
glands were filtered and mashed through a 70µm cell strainer. The cells were pelleted and
purified over a Percoll gradient as above.
For all tissues preparations, red blood cells were lysed using ACK lysing buffer
(ThermoFisher Scientific) for 5 minutes on ice, pelleted, and brought up in FACS buffer
(PBS+ 2%FBS+ 1mM EDTA).

7.2.2 Flow cytometry and cell sorting
Antibodies listed in Section 7.5 were diluted in FACS buffer (PBS + 2%FBS +
2mM EDTA) and used to stain single cell suspensions for 20 minutes in the dark at 4°C.
Cells were washed with FACS buffer and either fixed for intracellular staining or subjected
to flow cytometry. Dead cells were eliminated with DAPI, 7-AAD, or Live/Dead Aqua.
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For sorts, cells were sorted according to the following scheme: NK cells (CD3eNK1.1+ NKp46+ or CD3e- NK1.1+ CD49b+), CD4 T cells (CD19- CD3+ CD4+), CD8 T cells
(CD19- CD3+ CD8+), B cells (CD3- CD19+), macrophages (F4/80+ CD11b+), liver NK cells
(CD3e- NK1.1+ NKp46+ CD49a- CD49b+), liver ILC1 (CD3e- NK1.1+ NKp46+ CD49a+
CD49b-), small intestine ILC2 (Lin- CD45.2+ CD90.2+ CD127+ KLRG1+), small intestine
ILC3 (Lin- CD45.2+ CD90.2+ CD127+ KLRG1-), lung ILC2 (Lin- CD45.2+ CD90.2+ T1/ST2+).
The gating strategy for sorting CLP and NK cell progenitors is depicted in Figure 11.
Lineage (Lin) markers included CD3, CD4, CD8, CD11b, CD11c, Ly6G, NK1.1, and
Ter119.
To sort NK cells for culture, up to 5 spleens were pooled, stained with a lineage
antibody cocktail against CD3, CD4, CD8, CD19, and Ter119; these cells were depleted
with Anti-Rat IgG magnetic beads (Qiagen). Cells were subsequently stained with
antibodies to NK1.1 and NKp46 or CD49b. Live cells were sorted as DAPI- Lin- NK1.1+
NKp46+ or DAPI- Lin- NK1.1+ CD49b+. Cell sorting was performed on a FACS Aria II (BD
Biosciences). Flow cytometry was performed on an LSR-II (BD Biosciences).
Transcription factor staining was done using the FoxP3 Transcription Factor Staining Kit
(ThermoFisher Scientific) according to the manufacturer’s instructions. Incorporation of
BrdU was detected using the BrdU staining buffer set (ThermoFisher Scientific) according
to the manufacturer’s instructions.
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7.2.3 Intracellular cytokine staining
Leukocytes isolated from spleen, liver, lung parenchyma, and small intestine
lamina propria were plated in 96-well round bottom plates in DMEM+ 5% FBS+ 20mM
HEPES+ and 1X Penicillin/Streptomycin and held at 37°C. Media containing the indicated
cytokines (final concentration 20ng/mL) or PMA (Sigma; final concentration 100ng/mL)
and Ionomycin (Sigma; final concentration 10ng/mL) was then added to the appropriate
wells. Cytokine secretion was blocked with Brefeldin A (Sigma). The cell suspensions
were stimulated for 4-5h at 37°C. For intracellular cytokine detection, cells were washed
and fixed with Cytofix/cytoperm (BD Biosciences) or Foxp3 Transcription Factor Staining
Kit and permeabilized with Permeabilization Buffer (ThermoFisher Scientific) according to
the manufacturer’s instructions.

7.2.4 BrdU Labeling
For BrdU labeling experiments, mice were injected with 1mg Bromodeoxyuridine (Sigma)
in 200uL PBS every 12h for three days and sacrificed for analysis 12hr after the final
administration.

7.2.5 In vivo RMA challenge
Prior to the experiment, RMA cells were labeled with CFSE (ThermoFisher
Scientific) and RMA-S were labeled with Cell Trace Violet (CTV; ThermoFisher Scientific)
according to the manufacturer’s instructions. 5x106 CFSE-labeled RMA cells (MHC-I+) and
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15x106 CTV-labeled RMA-S (MHC-I-) cells were combined in 200uL of PBS in injected
intravenously into recipients. After 16h, the recipient mice were euthanized and
splenocytes were analyzed by flow cytometry. The results were determined by taking the
ratio of RMA:RMA-S cells remaining in the spleen at this time.

7.2.6 Listeria monocytogenes and Salmonella Typhimurium infections
For Listeria infections, mice were injected i.v. with 3x104 CFU of Listeria monocytogenes
1043S. The mice were sacrificed 3 days post infection and their spleens and livers were
collected for flow cytometry and CFU analysis. For Salmonella infections, mice were
fasted 12 hours prior to oral gavage with 5-7x10^7 CFU of Salmonella enterica serovar
Typhimurium (strain SL1344). Food was returned to mice immediately post infection. Mice
were sacrificed day 5 post infection and their organs were collected and homogenized for
flow cytometry and CFU analysis.

7.2.7 Papain challenge
Papain challenge was done by anesthetizing mice with Isoflurane and
administering 30µg of Papain in 30µL PBS every 24 hours for five days. Mice were
sacrificed for analysis 24hr after the last challenge.
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7.2.8 Intranasal IL-33
To elicit lung ILC2 expansion, we intranasally administered recombinant murine
IL-33 (Biolegend). Mice were anesthetized with Isoflurane and treated with 250ng IL-33
diluted in 25µL PBS every 24 hours for 4 days. Mice were sacrificed for sorting 24 hours
after the last administration.

7.2.9 In vivo IL-2/aIL-2 treatment
To generate IL-2/aIL-2 complexes for the in vivo expansion of mouse NK cells, we
incubated 1.5µg recombinant murine IL-2 (Peprotech) with 10µg aIL-2 (S4B6; BioXcell) in
50uL sterile PBS at 37°C for 30 minutes. The complexes were then diluted to 200µL in
PBS and injected i.p. into mice every other day for a total of three administrations. Mice
were sacrificed 24 hours following the final administration.

7.2.10 Bone marrow chimeras
To generate competitive bone marrow chimeras, bone marrow from either Rroid+/+
CD45.1+CD45.2+ or Rroid-/- (CD45.2+) donor mice was isolated by flushing. Following red
blood cell lysis, donor cells were counted and mixed 1:1. A total of 1x106 donor bone
marrow cells were transferred intravenously into lethally irradiated (2x550rad given 3h
apart) CD45.1+ hosts. Recipients were maintained on water supplemented with Sulfatrim
for two weeks following the transfer. Mice were sacrificed for analysis 8 weeks following
transfer.
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7.2.11 Retroviral transduction
Retrovirus for transducing Rroid-/- bone marrow was generated as previously
described201. Briefly, Id2 cDNA was cloned into the MSCV-IRES-GFP plasmid. Empty or
Id2-expressing retrovirus were produced in 293T human embryonic kidney cells with
MSCV expression and pCL-Eco packaging plasmids using Lipofectamine 3000
(Invitrogen) according to the manufacturer’s instructions.
Bone marrow for transduction was isolated by flushing femurs and tibias from
Rroid-/- mice 4 days after treatment with 5mg 5-Fluorouracil. Bone marrow cells were
seeded

at

2.5x106

cells/mL

in

a

6-well

plate

in

IMDM+

15%

FBS+

1X

Penicillin/Streptomycin+ 10ng/mL IL-3+ 5ng/mL IL-6+ and 100ng/mL SCF (Biolegend) and
cultured overnight. Cultures were readjusted to 5x106 cells/mL in 1mL culture medium,
and 1mL of retroviral supernatants supplemented with 10µg/mL Prolybrene (EMD
Millipore) was added to the appropriate wells. Cells were spinfected at 230xg for 2h at
room temperature, then incubated at 37°C overnight. Transduced bone marrow was then
washed and transferred to lethally irradiated hosts. The day before transfer, CD45.1+
congenic recipients were irradiated with 2x550rad given 3h apart. Mice were analyzed 6
weeks following transfer.

7.2.12 STAT4 and STAT5 posphorylation
To assess STAT5 phosphorylation in splenic NK cells, splenocytes were counted
and 2.5x106 cells plated in 100µL culture medium in a round-bottom plate. The cells were
rested for 1 hour at 37°C. Separately, serial 10-fold dilutions were made to prepare 2X IL145

15/IL-15Ra stocks consisting of 200ng/mL to 0.02ng/mL and 60ng/mL to 0.006ng/mL in
culture medium. At t=0, 100µL of the 2X cytokine mix was added to the splenocytes and
mixed, covering a final range of 100ng/mL to 0.003ng/mL IL-15/IL-15Ra, and incubated
for 1 hour at 37°C. Cells were fixed by adding 50µL of 10% Paraformaldehyde (Electron
Microscopy Sciences) and incubating 15 minutes at 37°C. The fixed cells were pelleted
and washed 2x with FACS buffer. The fixed cells were placed on ice and permeabilized
by adding 100µL of ice-cold methanol and incubated for 30 minutes at -20°C. The cells
were thoroughly washed 2x with FACS buffer and subsequently stained for flow cytometry.
For STAT4 phosphorylation, splenocytes were plated and rested as above for 1h at 37°C,
then stimulated with 20ng/mL of IL-12 for the indicated times and processed as above.

7.2.13 In vitro stimulation and NK cell expansion
Sorted splenic NK cells were expanded in NK cell culture medium (RPMI+ 10%
FBS+ 1X Penicillin/Streptomycin+ 1X 2-Mercaptoethanol (Gibco)) and supplemented with
20ng/mL recombinant IL-15/IL-15Ra complexes for 7-8 days. For Id2 and Rroid induction,
expanded NK cells were washed 2x in PBS and 5x105 cells were plated 500µL of culture
medium without cytokines and allowed to rest at 37°C for 4 or 5 hours. Following this
period, 500uL of pre-warmed culture media containing IL-15/IL-15Ra complexes to a final
concentration of either 0.5ng/mL or 5ng/mL IL-15/IL-15Ra complexes and cultured for an
additional 3h.
For in vitro T cell stimulation, 2x105 sorted splenic CD4+ or CD8+ T cells were
plated in T cell culture medium (RPMI+ 10% FBS+ 20mM HEPES+ 1X L-Glutamine
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(ThermoFisher Scientific)+ 1X Sodium Pyruvate (ThermoFisher Scientific)+ 1X 2Mercaptoethanol+ 1X Nonessential amino acids (ThermoFisher Scientific)+ 1X
Penicillin/Streptomycin) in 48 well plates pre-coated overnight with 5µg/mL anti-CD3 (1452C11, ThermoFisher Scientific) and 1 µg/mL soluble anti-CD28 (37.51, ThermoFisher
Scientific). For Th0 conditions, the media was supplemented with 100U/mL recombinant
human IL-2; for Th1-skewing conditions, the media contained 100U/mL IL-2+ 20ng/mL IL12, and 10ng/mL anti-IL-4. For CD8+ T cells, the media contained 100U/mL IL-2.

7.2.14 In vitro locked nucleic acid treatment
For in vitro Rroid knockdown by locked nucleic acids (LNAs), we first sorted and
expanded splenic NK cells as described above. After collection, 4x106 NK cells were
combined with 4µM control LNA or a mix of four LNAs specifically targeting Rroid and
transfected via nucleofection in an Amaxa Nucleofector 2b device using the Mouse T cell
Nucleofector kit (Lonza) according to the manufacturer’s instructions and maintained in
NK cell culture medium supplemented with IL-15/IL-15Ra complexes for the indicated
times.

7.2.15 RNA isolation, cDNA synthesis, and qPCR
Total RNA was isolated from mouse tissues or sorted cells using TRIzol
(ThermoFisher Scientific) according to the manufacturer’s instructions. Glycogen (Roche)
was used as a carrier. Isolated total RNA was quantified using a Nanodrop 1000. cDNA
was synthesized using SuperScript II Reverse Transcriptase (ThermoFisher Scientific)
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according to the manufacturer’s instructions using oligo-dT primers. qPCR was performed
using SYBR Green (KAPA SYBR Fast; KAPA Biosystems) using the indicated primers. In
some experiments, 2500 liver ILC1s or NK cells were sorted and used as input for the
Cells-to-Ct 1-step Taqman qPCR kit (ThermoFisher Scientific). All qPCR reactions were
performed in duplicate or triplicate on a CFX96 Touch system (Bio-Rad) or ViiA7 RealTime PCR instrument (ThermoFisher Scientific). The primers used for qPCR are listed in
Section 7.6.

7.2.16 ChIP-qPCR
Splenic NK cells for ChIP-qPCR on histone marks were expanded in vivo using IL2/aIL-2 complexes and sorted to high purity. To assess STAT5 recruitment to the Id2
promoter, NK cells were expanded in vitro as described, rested, and stimulated for 1 hour
with 20ng/mL IL-15/IL-15Ra complexes before fixation. NK cells were collected and fixed
with 1% Paraformaldehyde for 5 minutes at room temperature, and the reaction was
quenched by the addition of 0.125M glycine. The fixed cells were washed twice with ice
cold PBS and nuclei were prepared by incubating with lysing buffer (50mM Tris, pH
8.0+140mM NaCl+1mM EDTA, pH 8.0+10% Glycerol+0.5% NP-40+0.25% Triton X-100)
for 10 minutes on ice. The nuclei were then washed twice with 10mM Tris, pH 8.1+200mM
NaCl+1mM EDTA, pH8.0. Nuclei were resuspended in shearing buffer (10mM Tris, pH
8.1+1mM EDTA, pH8.0+ 0.1% SDS) and sonicated 90 seconds using a Covaris S220
(140W, 10% duty factor, 200 cycles per burst) to obtain ~400-500bp fragments. Sheared
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chromatin aliquots containing an equivalent 1x106 nuclei were flash frozen and stored at
-80°C.
For ChIP-qPCR on histone marks, an equivalent of 1x106 nuclei of sheared
chromatin was used as input and diluted to 1mL using IP dilution buffer (20mM Tris,
pH8.1+ 2mM EDTA, pH8.0+ 150mM NaCl+ 1% Triton X-100+ 0.01%SDS). For STAT5
pulldown, 3x106 nuclei were used. Protein G magnetic beads (ThermoFisher Scientific)
were pre-loaded with 1.5µg of anti-H3K27ac (ab4729; Abcam), anti-H3K36me3 (ab9050;
Abcam), or 5µg of anti-STAT5A/B (AF2168; R&D Systems) and incubated with the
chromatin overnight at 4°C. Beads were washed once in low salt buffer (20mM Tris,
pH8.1+ 2mM EDTA+ 50mM NaCl+ 1% Triton X-100+ 0.1% SDS), once in high salt buffer
(20mM Tris, pH8.1+ 2mM EDTA+ 500mM NaCl+ 1% Triton X-100+ 0.1% SDS), once in
LiCl buffer (10mM Tris, pH 8.1+ 1mM EDTA+ 0.25mM LiCl+ 1% NP-40+ 1% deoxycholic
acid) and twice in TE buffer (10mM Tris-HCl, pH8.0+ 1mM EDTA). Washed beads were
eluted twice with 100 μL of elution buffer (1% SDS+ 0.1M NaHCO3) and de-crosslinked
(0.1 mg/ml RNase, 0.3 M NaCl and 0.3 mg/ml Proteinase K) overnight at 65°C. The
samples were purified with Qiaquick PCR columns (Qiagen). qPCR was performed in
triplicate using KAPA SYBR Fast on a ViiA7 Real-Time PCR instrument (ThermoFisher
Scientific) using the primers listed in Section 7.6.

7.2.17 Chromatin Conformation Capture (3C)
To prepare nuclei for 3C assays, splenic NK cells were sorted and expanded for 7
days. Cells were fixed at room temperature for 10min at a concentration of 10x106 cells/mL
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in 2% Paraformaldehyde in PBS, then the reaction was quenched with the addition of
0.125M glycine and placed on ice for 10 minutes. The cells were pelleted and nuclei
collected by incubating in lysing buffer (50mM Tris, pH 8.0+140mM NaCl+1mM EDTA, pH
8.0+10% Glycerol+0.5% NP-40+0.25% Triton X-100) for 20 minutes on ice. Lysis was
monitored by methyl-green pyronin staining (Bio-rad). The nuclei were pelleted, snap
frozen, and stored at -80°C.
For 3C assays, nuclei were thawed and resuspended in 500µL 1X NEBuffer 2.1.
To lyse the nuclei and strip chromatin-bound proteins, 2.5µL of 20% SDS was added and
nuclei were incubated for 10min at 65°C; the reaction was quenched with the addition of
26.5µL of 20% Triton X-100 and incubated for 1h at 37°C with shaking at 120rpm. 500U
of HindIII-HF was then added and the nuclei were digested overnight at 37°C with shaking
at 120rpm. This reaction was stopped by the addition of 40µL of 20% SDS and incubating
25min at 65°C. The nuclei were transferred to a 50mL conical tube and diluted with
6.125mL ligation buffer. 375µL of 20% Triton X-100 was added and the nuclei were
incubated for 1h at 37°C. The nuclei were then ligated for five hours with 6667 Cohesive
End Units of T4 DNA Ligase (NEB) at 16°C with shaking at 120rpm. Crosslinks were
reversed by addition of 100uL of 10mg/mL Proteinase K (Roche) overnight at 65°C. The
template was then treated with RNase A for 30min at 37°C with shaking at 120rpm. The
3C template was then purified with saturated phenol-chloroform (Sigma) extraction.
Digestion efficiency was confirmed by qPCR after sampling the template before and after
digestion, reversing crosslinks, and extracting the DNA.
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To control for PCR efficiency, two BACs containing the loci of interest (RP23300A18 and RP23-342B; Bacpac) were mixed at equimolar concentrations and digested
overnight with 500U of HindIII-HF. The digested BAC template was then extracted via
saturated phenol-chloroform, brought up in 200uL of ligase buffer, and ligated overnight
in 6667 Cohesive End Units of T4 DNA ligase overnight at 16°C. The BAC template was
then isolated by saturated phenol-chloroform extraction. Both BAC and 3C ligation
products were amplified by qPCR using SYBR Fast Master Mix on a CFX96 Touch
System. The products were visualized on a 2% agarose gel, imaged using a ChemiDoc
MP system, and band intensity was quantified using Fiji202. The band intensity of 3C
products was normalized to that of the respective BAC control product.

7.2.18 RNA-seq
The RNA-seq tracks in Figure 4A and B were from GSE77695 and
GSE8515479,80. For RNA-seq from Rroid-/- NK cells, total RNA was isolated from sorted
CD27+ CD11b+ NK cells using a combination of TRIzol and RNeasy Micro columns
(Qiagen). The aqueous phase from the TRIzol-chloroform extraction was precipitated with
ethanol, applied to RNeasy Micro columns and processed according to the manufacturer’s
instructions. The RNA libraries were generated using the Ovation RNA-Seq System V2
(Nugen) and the KAPA Hyper Prep Kit (KAPA Biosystems). Sequencing was performed
on the HiSeq2500. The resulting reads were trimmed and aligned to the NCBIM37/mm9
genome using Tophat2. Transcript counts were generated using HTSeq and differential
gene analysis was performed using DESeq2.
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To identify Id2-dependent genes for GSEA, RNA-seq reads from GSE7646655
were analyzed using Tophat2, HTSeq, and DESeq2 as described previously. Up- and
downregulated differentially expressed genes (FDR<0.05) were used as input gene sets.
GSEA was performed using gseapy.

7.2.19 ATAC-seq and peak calling
The ATAC-seq tracks in Figures 4, 23, and 26 were from GSE7769579. ATAC-seq
for Rroid-/- NK cells was done on Illumina NextSeq at a sequencing depth of ~60-70 million
reads per sample. Libraries were prepared in triplicate. 2x75 bp paired end reads were
mapped to the mouse mm9 reference genome using ‘bwa’ algorithm with ‘mem’ option
with default parameters203. Only reads that uniquely mapped to the genome were used in
subsequent analysis. Duplicate reads were eliminated to avoid potential PCR amplification
artifacts and to eliminate high number of mtDNA duplicates observed in ATAC-seq
libraries. Post-alignment filtering resulted in ~30-40 million uniquely aligned singleton
reads. ATAC-seq enriched regions (peaks) in each sample was identified using MACS2204.
Only peaks called with a peak score (q-value) of 1% or better were used in downstream
analysis. Peak annotation was performed via HOMER v4.6 annotatePeaks.pl for the mm9
assembly. Differentially open chromatin loci were identified using R Bioconductor DiffBind
package.
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7.2.20 Transcription factor footprinting
For transcription factor (TF) footprinting, we used the Protein Interaction
Quantification (PIQ) algorithm205 to quantify TF binding events based on ATAC-seq
chromatin accessibility profiles. We merged JASPAR motifs206 with SELEX-based
motifs207 and generated a set of 480 TFs as input to PIQ footprint calls. For each putative
TF binding event, PIQ outputs a purity score reflecting the probability of TF binding to that
locus. We have included only footprint calls with >0.9 purity score in the subsequent
analyses.

7.3 Quantification and statistical analysis
Statistical analyses were performed in Prism 7 using unpaired, two-tailed Student’s
t-test or one way ANOVA with Tukey’s post hoc, as indicated. In all cases p£0.05 was
considered statistically significant. All error bars represent S.E.M.

7.4 Data and software availability
The raw data for the RNA-seq and ATAC-seq reported in this thesis have been deposited
in GEO under the accession number GSE101459
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7.5 List of antibodies and cytokines
Antibodies
Anti-mouse CD3 (clone: 145-2C11)

ThermoFisher Scientific

47-0031-82,
16-0031-85

Anti-mouse CD4 (GK1.5)

Biolegend

100406

Anti-mouse CD8 (53-6.7)

Biolegend

100706

Anti-mouse/human CD11b (M1/70)

Biolegend

101212

Anti-mouse CD11c (N418)

Biolegend

117317

Anti-mouse CD19 (1D3)

ThermoFisher Scientific

47-0193-82

Anti-mouse CD25 (3C7)

Biolegend

101915

Anti-mouse/rat/human CD27 (LG.3A10)

Biolegend

124216

Anti-mouse CD28 (37.51)

ThermoFisher Scientific

16-0281-85

Anti-mouse CD45.1 (A20)

Biolegend

48-0453-82

Anti-mouse CD45.2 (104)

Biolegend

109822

Anti-mouse CD49a (HMa1)

Biolegend

142604

Anti-mouse CD49b (DX5)

Biolegend

108910

Anti-mouse CD90.2 (30-H12)

Biolegend

105324

Anti-mouse CD107a (1D4B)

Biolegend

121612
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Anti-mouse/pig CD117 (2B8)

ThermoFisher Scientific

47-1171-80

Anti-mouse CD122 (TM-b1)

Biolegend

123213

Anti-mouse CD127 (A7R34)

Biolegend

135010

Anti-mouse 2B4 (m2B4(B6)458.1)

Biolegend

133508

Anti-mouse a4b7 Integrin (DATK32)

Biolegend

120612

Anti-BrdU (Bu20a)

Biolegend

339812

Anti-mouse Eomes (Dan11mag)

ThermoFisher Scientific

50-4875-82

Anti-mouse F4/80 (BM8)

Biolegend

123113

Anti-mouse Flt3 (A2F10)

Biolegend

135314

Anti-mouse GATA3 (L50-823)

BD Biosciences

135314

Anti-mouse IFN-g (XMG1.2)

Biolegend

505826

Anti-mouse IL-2 (S4B6)

BioXcell

BE0043-1-5MG

Anti-mouse IL-4 (11B11)

Biolegend

504107

Anti-mouse IL-5 (TRFK5)

ThermoFisher Scientific

12-7052-81

Anti-mouse IL-13 (eBio13A)

ThermoFisher Scientific

53-7133-80

Anti-mouse IL-22 (IL22JOP)

ThermoFisher Scientific

17-7222-82

Anti-mouse Ly6G (1A8)

Biolegend

127606
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Anti-mouse MHC-II (M5/114.15.2)

Biolegend

107621

Anti-mouse NK1.1 (PK136)

Biolegend

108745

Anti-mouse NKp46 (29A1.4)

Biolegend

137606

Anti-mouse Rorgt (B2D)

ThermoFisher Scientific

12-6981-82

Anti-mouse Sca-1 (D7)

Biolegend

108131

Anti-mouse Siglec-F (E50-2440)

BD Biosciences

552126

Anti-mouse p-STAT4 (38/pSTAT4)

BD Biosciences

558137

R&D Systems

AF2168

Anti-mouse p-STAT5 (47/Stat5(pY694))

BD Biosciences

612567

Anti-mouse T1/ST2 (Biotin; DJ8)

MD Bioproducts

101001B

Anti-mouse/human T-bet (4B10)

Biolegend

644824

Anti-mouse TCRb (H57-597)

Biolegend

109212

Anti-mouse Ter119 (TER-119)

Biolegend

116206

Anti-H3K27ac (Rabbit polyclonal)

Abcam

ab4729

Anti-H3K36me3 (Rabbit polyclonal)

Abcam

ab9050

Streptavidin

Biolegend

405207

7-AAD

Sigma

A9400-1MG

Anti-mouse/human

STAT5A/B

(Rabbit

polyclonal IgG)
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DAPI

Sigma

D9542-5MG

Live/Dead Aqua

ThermoFisher Scientific

L34966

Chemicals, Peptides, and Recombinant Proteins
BrdU

Sigma

B5002-1G

Papain

Millipore

5125-50GM

Liberase TM

Sigma

5401127001

Collagenase D

Sigma

11088866001

Collagenase 4

Worthington Biochemical

LS004188

DNase I

Sigma

DN25-1G

Percoll

GE Healthcare

17-0891-01

Recombinant human IL-2

Peprotech

200-02

Recombinant mouse IL-2

Peprotech

212-12

Recombinant mouse IL-3

Biolegend

575502

Recombinant mouse IL-6

Biolegend

575702

Recombinant mouse IL-12

Biolegend

577002

Recombinant mouse IL-15/IL-15Ra

ThermoFisher Scientific

14-8152-80

Recombinant mouse IL-18

MBL International

B002-5
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Recombinant mouse IL-23

ThermoFisher Scientific

14-8231-63

Recombinant mouse IL-33

Biolegend

580504

Recombinant mouse SCF

Biolegend

579702

7.6 List of primers
CRISPR sgRNA
sequences
Target
Rroid-5' sgRNA
Rroid-3' sgRNA
Rroid-P1-5' sgRNA
Rroid-P1-3' sgRNA
Rroid-RE1-5' sgRNA
Rroid-RE1-3' sgRNA
Id2-DS2-5’ sgRNA
Id2-DS2-3’ sgRNA
Id2-DS3-5’ sgRNA

Id2-DS3-3’ sgRNA
Genotyping Primers
Target
Rroid_geno_WT_F

Sequence
GATTCACAGGCACTTGTTTCGTTTTAGAGCTAGAAATAGCAAG
TTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
GAGTCGGTGCTTTTTT
GCTATAGGTGTTAATTCTGTGTTTTAGAGCTAGAAATAGCAAG
TTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
GAGTCGGTGCTTTTTT
GTATGATAAACTCACAATGGGTTTTAGAGCTAGAAATAGCAAG
TTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
GAGTCGGTGCTTTTTT
TCGCTTCAGAGGGCACTATAGTTTTAGAGCTAGAAATAGCAA
GTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC
CGAGTCGGTGCTTTTTT
TGTCCAAGGATGTCCATATTGTTTTAGAGCTAGAAATAGCAAG
TTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
GAGTCGGTGCTTTTTT
CATCCGAAGATCCCTGTATGGTTTTAGAGCTAGAAATAGCAA
GTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC
CGAGTCGGTGCTTTTTT
GACTTGTGGGACAATCAGTTGTTTTAGAGCTAGAAATAGCAA
GTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC
CGAGTCGGTGCTTTTTT
CTTTGCAGTTAAGCCCGGGGGTTTTAGAGCTAGAAATAGCAA
GTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC
CGAGTCGGTGCTTTTTT
CGTACGTAAGTCATCAGCCCGTTTTAGAGCTAGAAATAGCAA
GTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC
CGAGTCGGTGCTTTTTT
GAAGGCTATATCAACTTAGTGTTTTAGAGCTAGAAATAGCAAG
TTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
GAGTCGGTGCTTTTTT
Sequence
GGGGACAGAGGGTGAAAGTG
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Rroid_geno_WT_R
Rroid_geno_KO_F
Rroid_geno_KO_R
RroidP1_geno_common_F
Rroid-P1_geno_WT_R
Rroid-P1_geno_KO_R
RroidRE1_geno_common_F
Rroid-RE1_geno_WT_R
Rroid-RE1_geno_KO_R
Id2-DS2_WT_F
Id2-DS2_WT_R
Id2-DS2_KO_F
Id2-DS2_KO_R
Id2-DS3_WT_F
Id2-DS3_WT_R
Id2-DS3_KO_F
Id2-DS3_KO_R
Gene expression qPCR
primers
Target
Hprt1-F
Hprt1-R
Rroid-F
Rroid-R
Id2-F
Id2-R
Ets1-F
Ets-1-R
Il12rb1-F
Il12rb1-R
Il12rb2-F
Il12rb2-R
Nfil3-F
Nfil3-R
Prf1-F
Prf1-R
Tbx21-F
Tbx21-R
Tcf7-F
Tcf7-R
Tox-F
Tox-R

CACAAGGGATTGTCTCCGCT
CACCTGAGGGATGATGGTCT
AGGTGAGCAGAAGCAGCAAT
CAGGCTCTCTGATTCCATGC
TGCAGAAGAGAAGGGGCTAA
CCTGGATGAGAGCTGGCTAC
ATCCCAGGACCATGTAGCAC
GGTGAACAGCCAGGAAATGT
TGCCAAAAGCCCATCTTATC
GTGTGTTGGGAGGACAGAGG
GCACTTGCACATGAGCACAA
TGACCTCCCAAGCAAGGATG
CGCCACTGGTGTAAGCCATA
GAGGGCACCCAGCTGCAAGG
AGCTCTTGGCGCAGTGCTGG
TAGGCGCTCCACAGACCGGA
GAGCGAGGGAGGGACGGGAG

Sequence
TCAGTCAACGGGGGACATAA
GGGGCTGTACTGCTTAACCAG
GCATGGCTGAGTCCTCTTTC
TGAATTGGGGGAAATGATGT
CCTGAACACGGACATCAGC
CACAGAGTACTTTGCTATCATTCG
CTGACCTCAACAAGGACAAGCC
TTCCAGAAGAAACTGCCACAGC
ACTGGAATGTGTCTGAAG
CGTATCTGGATCTCTTGG
CCTCAATGGTATAGCAGAAC
TAGCCTTGGAATCCTTGG
GCTCCTTTTTGATGGTCTGC
TTCCTGCTCTGATTGCCTTT
GAGAAGACCTATCAGGACCA
AGCCTGTGGTAAGCATG
AACTGTGTTCCCGAGGTGTC
AATCGACAACAACCCCTTTG
AAGGTCATTGCTGAGTGCACAC
TGCATGCCACCTGCGAC
TGCCTGGACCCCTACTATTG
CTGGCTGGCACATAGTCCTG
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Hprt1
Il12rb2

Mm00446968_m1
Mm00434200_m1

ChIP qPCR primers
Target
Id2pro.A_F
Id2pro.A_R
Id2pro.B_F
Id2pro.B_R
Id2pro.C_F
Id2pro.C_R
Id2pro.D_F
Id2pro.D_R
Id2pro.E_F
Id2pro.E_R
Id2pro.F_F
Id2pro.F_R
Id2pro.Stat5_F
Id2pro.Stat5_R
Gapdh

Sequence
CCTTGGTCTGTGCCCTTCA
GACAAAGAGCTTCCCAAGAGC
TATACCCGCCCCCAGGAC
CGCGCTTCTTTTCCCTTC
GCGGGGCGTCTTTTATGT
ACGCGGAAGAACCGAGAG
TGGGCAGTGGCGTACTTG
CTCGCATCCCACTATCGTCA
GCGTCATGGAGGAAATGATG
TGCAGGCAGTACACACCTGA
CTCCCCATGGTGGGAATAG
GCCCAGGTGTCGTTCTCC
TAGCGTTAGGGAAGACAGCGAC
GTCGTGGACGTGTATGTGGGTA
Qiagen (GAM-9205)

Locked nucleic acids
Target
Rroid_1
Rroid_2
Rroid_3
Rroid_4
Control

Sequence
AGAATGAAGCAAAGTC
TGAGGATGACTGTAAT
TTAGTAGTGAGGTGC
ACAGGACAGAAAGAAT
AACACGTCTATACGC

3C Primers
Target
Id2_3c_digesttest_F
Id2_3c_digesttest_R
Id2_3c_digesttest_control
_F
Id2_3c_digesttest_control
_R
Id2_3c_C1
Id2_3c_T1
Id2_3c_T2
Id2_3c_T3
Id2_3c_T4
Id2_3c_T5
Id2_3c_T6

Sequence
CAGCGACCGTGGCAGAAGGG
GGGGCTCCTCTGCGGTCTGA
TATACCCGCCCCCAGGAC
CGCGCTTCTTTTCCCTTC
CGCTTTTGGGAAGTCACATT
CCAGGACCTCTGGGTGTAGA
CAGGCCTTCCTGACTTCAAA
ACTCTGCACCTGGAGGACAC
ACTAGATGGGCAGCAGAGGA
AGCAATGTCTGAGGCAGCTT
TGGTTACAGGTGGCAGTGAG

160

Id2_3c_T7
Id2_3c_T8
Id2_3c_T9
Id2_3c_T10
Id2_3c_T11
Id2_3c_T12
Id2_3c_T13

TTCAAAAAGATTAAAGTTGTGATTCC
CTGGAAGGGTGAGGACCATA
CAGCTGGGGATTTCTGTGTT
GCCATAGCTGTCTCCTGCTT
GGGTCACCAGCATGAATACC
TCTTCCTGACCCACATTCCT
CTCACCCCAGTACCTTCCAG
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